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ABSTRACT
It is well established that improper protein folding often leads to the formation of
aggregates whose consequences are cellular impairment and cell death. One example
of this is the aggregation of the mutant Z Alpha1-Antitrypsin protein, which results in
blocking of its secretion due to inclusion body formation. This can contribute not only to
the development of chronic obstructive pulmonary disease but also to hepatitis, cirrhosis
and hepatocellular carcinoma. Current treatments are principally limited to intravenous
Alpha1-Antitrypsin therapy and organ transplantation. In the scientific community
though, it is widely thought that more effective forms of treatments lie within the
polymerization process itself. However, in order to conduct the necessary experiments
for this, copious amounts of Alpha1-Antitrypsin protein are needed. The amounts far
out-weigh those that are obtainable through traditional methods of plasma purification.
Therefore there is a high demand for methods that can successfully produce
recombinant Alpha1-Antitrypsin protein. Over the years, several systems have been
implemented to produce wild-type Alpha1-Antitrypsin protein but it was not until 2009
that recombinant Z Alpha1-Antitrypsin protein was successfully produced. The goal of
this thesis was to expand upon this original study in order to produce both untagged and
tagged versions of recombinant Z Alpha1-Antitrypsin protein using the methylotrophic
yeast, Pichia pastoris. Colonies from the protease-deficient strand SMD1163 were
selected for multi-copy integrations and then purified using affinity chromatography and
anion exchange chromatography. While the results of the purification process proved
inconclusive, they do help lay the groundwork for future endeavors.
v
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CHAPTER 1:
LITERATURE REVIEW

1.1 Serpins and Disease
a) Overview
With members identified in all major branches of life, Serpins are the most widely
distributed family of protease inhibitors (1,2). The inhibitory activity of serpins relies on
the structural flexibility of their Reactive Center Loop, which, in its native form, is not in
the most stable conformation.

In fact, the inhibitory native folded state is in a

metastable conformation, making it vulnerable to mutations (1,2). These mutations,
alone or in association with other factors, can upset the fragile balance within the serpin
structure and promote self-association and tissue deposition. The result of these selfassociation and tissue depositions is a group of diseases referred to as the
serpinopathies. Clinical manifestations of serpinopathies vary greatly, ranging from
emphysema to thrombosis to dementia (1,2).
In this section we will go into more detail about what exactly serpins are, their
structure, and common mutations that arise within them that lead to disease. This
section will also briefly look at the cellular response that occurs as a result of serpin
polymers.
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b) What are Serpins?
Serine protease inhibitors (Serpins) are the largest family of protease inhibitors
and are best known for their conformational flexibility and management of crucial
regulatory functions in multicellular eukaryotes. In addition to eukaryotes, serpins have
also been identified in bacteria, archaea and even some viruses. To date, over 1,500
members have been identified, 36 of which are found in humans (2). Proteins in the
serpin superfamily have an average size of 350-400 amino acids and molecular weight
of 40-50kDa (3). While considered to be mid-sized proteins, they are actually relatively
large molecules when compared to other protease inhibitors such as basic pancreatic
trypsin inhibitor (BPIT, which is about 60 amino acids) (2).
In 2000, a phylogenetic study of the superfamily was conducted, which divided
eukaryotic serpins into 16 ‘clades’ (termed A-P) (4). This resulted in a classification
system where members are named SERPINXy where X is the clade and y is the
number within the clade. Most serpins, however, also have alternative names from
before the creation of the classification system. An example of this is SERPINA8 -member 8 in Clade A --which also known as Angiotensinogen (2).
The name “Serpin” is actually quite misleading. In fact, not all members of this
family are serine protease inhibitors and not all serine protease inhibitors are members
(1,5). Although most serpins do inhibit serine proteases, some of them have been found
to inhibit caspases and papain-like cysteine proteases, while others perform noninhibitory functions. In fact, serpins with non-inhibitory functions perform vital roles in a
broad range of biological capacities, including chromatin packing (the myeloid and
erythroid nuclear termination stage-specific protein or MENT), blood pressure regulation
2

(angiotensinogen), protein folding (heat shock protein 47 or hsp47), tumor progression
(mammary serine protease inhibitor or maspin) and hormone transport (cortisol- and
thyroxine-binding globulin) (1,5). In addition, there is a subfamily of serpins whose
inhibitory activity is increased after binding to heparin or other negatively charged
polyanions such as heparin sulfate and dermatan sulphate. This subfamily includes
heparin cofactor II, antithrombin, protease nexin 1 and plasminogen activator inhibitior-1
(PAI-1)(2,3). Table 1.1 gives additional examples of serpins and their associated
functions.
Despite this diversity in function, the serpin superfamily is highly conserved. In
fact, members share more than 30% amino acid sequence homology and a conserved
tertiary structure with the archetype serpin, !1-Antitrypsin (SERPINA1, AAT) (6). This
structure typically consists of 9 !-helices, 3 ß-sheets (A, B, C) and an exposed mobile
Reactive Center Loop (RCL) that stretches between ß-sheets A and C over a span of
about 20 residues (Figure 1.1A). Crystal structures from different serpins have revealed
five conformational states –native, cleaved, latent, ", and polymeric—with differences
arising primarily in the structure of the RCL (4). In the native conformation of inhibitory
serpins, the RCL acts as a psuedosubstrate for the targeted protease that, upon binding
at the scissile bond (P1-P1’), triggers a “mousetrap” mechanism. During this
mechanism, the RCL is cleaved and integrated as an additional strand into the ß-sheet
A (strand 4 or s4A). The protease, which has been covalently bonded with the RCL, is
flipped from the upper pole to the lower pole of the serpin and rendered useless (Figure
1.1 B and C) (1-8).
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Table 1.1 Functions and Dysfunctions of Human Serpins: Some of the 36 serpins
found in humans along with their function and involvement, if any, in disease.
Information was adapted from (2)
Serpin

Alternative name

Protease Target or Function

Involvement in Disease

SERPINA1

Alpha-1 Antitrypsin

Inflammatory response molecule;
Neutrophil elastatse inhibition

Deficiency results in emphysema;
Polymerization and retention in the
ER results in cirrhosis

SERPINA3

Alpha -1
Antichymotrypsin

Inflammatory response molecule;
Cathespin C inhibition

Deficiency results in emphysema

SERPINA5

Protein C Inhibitor
(PAI-3)

Active Protein C inhibition

Angioedema

SERPINA6

Corticosteroid-Binding Hormone transport; cortisol binding
Globulin

SERPINA7

Thyroxine-Binding
Globulin

Hormone transport; thyroxine binding Deficiency results in
hypothyroidism

SERPINA8

Angiotensinogen

Blood pressure regulation; aminoterminal cleavage by the protease
renin results in release of the
decapeptide of angiotensin I

SERPINB3

Squamous Cell
Carcinoma Antigen-1

Inhibit papain-like enzymes; crossclass inhibition of cathespins L & V

SERPINB5

Mammary Serine
Protease Inhibitor
(Maspin)

Prevents metastasis in breast cancer
and other cancers through
uncharacterized mechanism

SERPINB6

Proteinase-Inhibitor-6
(PI6)

Prevent inappropriate activity of
cytotixic apoptotic proteases;
Inhibition of cathepsin G

SERPINB9

Cytoplasmic
antiproteinase 9 (PI9)

Prevent inappropriate activity of
cytotoxic apoptotic proteases;
Inhibition of granzyme B

SERPINC1

Antithrombin

Thrombin and Factor Xa inhibition

Deficiency results in thrombosis

SERPIND1

Heparin Cofactor II

Thrombin Inhibition

May contribute to thrombotic risk
when combined with other
deficiencies

SERPINE1

Plasminogen Activator Thrombin, uPA, tPA and plasmin
Inhibitor-1 (PAI-1)
inhibition

SERPINE2

Proteinase nexin I
(P17)

uPA and tPA inhibition

SERPING1

C1 inhibitor

C1 esterase inhibition

SERPINH1

Heat-Shock Protein
47kDa (hsp47)

Protein folding; Chaperone for
collagens

SERPINI1

Neuroserpin (PI 12)

tPA, uPA and plasmin inhibition
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Deficiency linked to chronic fatigue

Certain variants linked to essential
hypertension

Down-regulation and/or
intracellular location linked to
tumor progression and overall
prognosis

Abnormal bleeding

Angioedema

Polymerization results in dementia

The change from a native to cleaved conformation, also referred as the Stressed
(S) to Relaxed (R) transition, brings the serpin into its lowest energy state and is
irreversible (“suicidal”). In addition, the transition from S! R acts as a signal that the
serpin-protease is ready for destruction and is usually taken away through binding to the
lipoprotein-related protein (LRP)(2,8).
The latent conformation is an alternative R state where the RCL is uncleaved but
is still able to insert into the ß-sheet A. This change in conformation transitions the once
native, active serpin into an inactive or non-inhibitory state that can drastically reduce
the active lifetime of the serpin. The latent state has been studied the most in PAI-1, but
it is also thought to occur in other serpins such as antithrombin, AAT and !1antichymotrypsin (4,9-11)
The last two conformational states—", and polymeric—have only recently been
characterized. The " structure was first observed in !1-antichymotrypsin, where it was
caused by a L55P mutation and resembled a ‘half-way house’ intermediate state. This
conformation involved the partial insertion of the RCL into the ß –sheet A and the partial
unraveling of Helix F, which inserted itself into the base of ß-sheet A in order to
complete the ß-sheet hydrogen bonding (2,3,8,11). The polymeric conformation on the
other hand has been the center of much controversy and will be discussed in detail later
in this chapter (Section 1.3c).

Regardless of the conformation, there are 4 other structural regions—
hinge, breach, shutter and gate-- that are characteristic of inhibitory serpins (Figure
1.1A) (3). The hinge region, a section of the RCL (P15-P9, towards the N-terminal)
(12,13), provides mobility during the S! R transition and therefore is crucial for RCL
5

conformation change. In fact, almost of all the residues in this region are conserved and
the insertion of P14 into ß-sheet A is required for inhibitory activity (14).
The breach and the shutter regions are the two other major areas that aid in
sheet opening, allowing insertion of the hinge region (15). The breach region is located
at the top of ß-sheet A and is the point of the RCL’s initial insertion (16), whereas the
shutter domain is near the center of ß-sheet A and contains the highly conserved
residues Ser-53 and Ser-56 that play an important role in serpin conformational
transitions (17,18).
Lastly, the gate region consists of strands 3 and 4 of ß-sheet C (s3C and s4C
respectively) and also contains several highly conserved residues. It has mostly been
studied during experiments that focus on PAI-1’s transition from an active to latent
conformation (9). As discussed before, in the latent state the RCL is uncleaved but fully
integrated into ß-Sheet A. In order for this to be accomplished, the RCL has to pass
around the ß-turn linking s3C and s4C in the gate region (19). Aside from PAI-1 and
antithrombin however, most serpins do not normally transition into the latent state in
vivo. Therefore it is believed that the residue conservation within the gate region may be
linked to native form maintenance and rather than latent state promotion (4).

c) How are they linked to disease?
While the conformational flexibility of the serpin structure is important to its
function, it also leaves the structure vulnerable to mutations. Such mutations can result
in deficiency or degenerative disorders that are collectively known as serpinopathies.

6

Figure 1.1.1. Serpin Structure and Inhibition Mechanism: A) Conserved Tertiary Structure of a Serpin with the central
ß-sheet A highlighted in green and important features as indicated. B) Serpin-Protease Docking complex and in which the
protease binds and cleaves at the P1-P1’ bond. C) Final Serpin-Protease Complex in which the protease has been flipped
over 60Å and its active site is distorted. (Adapted from (1))

7

Clinically, serpinopathies have been shown to result in uncontrolled activation of
proteolytic cascades, thrombosis, angioedema or even chronic obstructive pulmonary
diseases (COPD). (1-3,5,6,8,20).
Naturally occurring mutations have been identified throughout the serpin
structure. However the most common and typically the most detrimental mutations are
located within the shutter region (Table 1.2). These mutations cause an uncharacteristic
opening of central ß-sheet A and allow the RCL to partially insert within the opening.
Shutter region mutations not only impair the inhibitory mechanism by affecting RCL
insertion, but they also predispose the mutant to polymerization via a head-to-tail
association mechanism. These mutations have been implicated in the development of
various clinical symptoms of serpinopathies: angioedema (C1-inhibitor), thrombosis
(antithrombin) as well as lung and liver disease (!1-antichymotrypsin and !1Antitrypsin) (1,3,8).
Although

rare,

some

mutations

cause

uncharacteristic

serpin-protease

interactions. One example is the Pittsburg variant (Met358Arg) in AAT, which converts
the serpin into an effective thrombin inhibitor. While only one case has been reported,
the resulting increase in antithrombin activity led to a severe bleeding and ultimately
death during childhood (1,2,21). Another example would be the Enschede variant
(!Ala366) of !2-antiplasmin, where an extra Alanine is added to the RCL. This addition
interferes with the RCL’s ability to insert into ß-sheet A, causing the protein to behave
more like a substrate, rather than an inhibitor, of plasmin (1,2,22).
There are several serpin mutations that have been identified as promoters of the
disease-linked latent state. One such mutation is the Wibble variant (Thr85Met) in
8

antithrombin, where about 10% of the circulating serpin adopts the latent conformation
(2,3). Another example is "-!1-antichymotrypsin which, as previously described, adopts
an “intermediate” conformation as a result of the L55P mutation. It is thought that this
conformation may exist between native and polymeric conformations and might also
explain the loss of !1-antichymotrypsin activity associated with COPD patients with the
L55P mutation (2,3,8,11).
Some mutations may lead to diseases if they appear in one serpin but not in
another serpin. The mutation that arises at P17 gultamate in serpins is a notable
example of this phenomenon. Indeed, a mutation at this location was recently
discovered in herparin co-factor II (Glu428Lys) that, while linked to the serpin’s plasma
deficiency, was not associated with any clinical disease (8,23). However when this
same mutation is expressed in the Z variant of AAT (Glue342Lys), it not only leads to
conformational instability and polymerization of the serpin (Figure1.2A and C) but also
can manifest clinically as emphysema or cirrhosis (1-3,8). The Z variant and its
associated serpinopathy, !1-Antirypsin Deficiency, will be discussed in more detail later
on in the chapter (Section 1.3).
Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB) is an
autosomal dominant form of dementia that, like !1-Antirypsin Deficiency, is the product
of serpin polymerization. In FENIB, neuroserpin polymers accumulate and become
retained within sub-cortical neurons where they form periodic acid Schiff (PAS) positive,
diastase resistant inclusions, called Collin’s bodies (20). These Collin’s bodies are
similar to those seen in the Z variant of AAT (Figure 1.2).
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Table 1.2. Serpin Mutations Related to Disease
Serpin

Alternative name

Mutation

SERPINA3

Alpha -1
Antichymotrypsin

L55P (!)

Region
Affected
Shutter

P228L
SERPINC1

SERPIND1

Antithrombin

Heparin
Cofactor II

T85M
(Wibble)
T85L
F229L

Shutter

P54S/T
N158D
C85R
L99F

Shutter

E428L

Breach

Shutter
Breach

Shutter
Shutter

P433L
SERPINF2

Alpha-2antiplasmin

A366 added
(Enschede)

RCL

SERPING1

C1 inhibitor

F52S
P54L
A349T
V366M

Shutter
Shutter
Shutter
Shutter

F370S
P391S
S54L

Shutter

SERPINI1

Neuroserpin
(PI 12)

S49P
(Syracuse)

Shutter

S52R
(Portland)

Shutter

H338R

Shutter

G392E

Shutter

G392R

Shutter
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Disease Associated

Ref

Creates an 'half-way'
house conformation
Emphysema and cirrhosis

(2,3,8)

10% of circulating serpin
is latent
Thrombosis
Spontaneous
polymerization at elevated
body temperature
Thrombosis
Thrombosis
Thrombosis
Thrombosis

(2,3)

Plasma deficiency; not yet
shown to cause disease

(8)

Polymerization

(3)

(8)

(3)
(1,8)
(3,8)
(8)
(3)
(3)

substrate-like activity
upon protease binding

(1,2)

Angioedema
Angioedema
Angioedema
Angioedema
Angioedema
Angioedema
Angioedema

(3,8)
(8)
(8)
(8)
(8)
(8)
(3)

FENIB; Dementia,
tremor, seizures
terminally
FENIB; Myoclonus,
status epilepticus,
dementia
FENIB; Myoclonic
seizures, dementia,
tremor, dysarthia
FENIB; Myoclonus,
status epilepticus,
dementia, chorea
FENIB; Dementia,
epilepticus of slow-wave
sleep

(1,3,6,8,2
0)
(1,3,6,8,2
0)
(1,3,6,8,2
0)
(1,3,6,8,2
0)
(20)

There are currently five known mutations that result in FENIB: Ser49Pro,
Ser42Arg. His338Arg, Gly392Glu, and Gly392Arg (Table 1.2). The Ser49Pro (Syracuse)
mutation was first discovered in a large Irish-American family and had small diffuse
intra-neuronal neurosperin inclusions (Figure 1.2E) with an onset of symptoms between
45-60 years old. The second mutation, Ser42Arg (Portland), was shown to be a more
severe mutation with larger inclusions (Figure 1.2F) and an onset of about 24 years old.
The His338Arg was found in a third family with even more inclusions and an onset of
symptoms around 15 years old. The fourth mutation (Gly392Glu) is particularly
interesting because it caused the replacement of a conserved residue within the shutter
region which produced large multiple inclusions in every neuron (Figure 1.2G), an onset
of symptoms around 13 and death before 20 (1,3,6,8,20). Lastly, the Gly392Arg
mutation was identified recently in an 8-year-old girl who displayed a drastic intellectual
decline, seizures and epilepticus of slow-wave sleep (ESES) (20).
Cellular Response
Serpin polymers, it seems, do not activate the unfolded protein response in cells.
This is most likely due to the highly ordered nature of the retained protein. Soluble
misfolded monomers, on the other hand, are typically retained in the endoplasmic
reticulum (ER), where they are targeted into the ER-associated degradation (ERAD)
pathway.
Mutant serpins that are able to escape the ERAD and form homogenous ordered
dimers and polymers are eventually trapped inside inclusion bodies. These inclusion
bodies are insoluble and are no longer observed by the ER quality control (5).
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The accumulation of serpin polymers however, can lead to a calcium-dependent
activation of the transcription factor NF-#B via the regulator of G signaling 16 (RGS16)
as seen in Figure 1.3 (5,24). This activation appears to eventually trigger the premature
apoptosis that is observed in some serpinopathies (1).

1.2 Alpha1-Antitrypsin
a) Overview
Alpha1-Antitrypsin, also known as "1-antiprotease inhibitor, is viewed as the
model for the serpin family. Its main function is to protect the lungs from neutrophil
elastase, a serine protease secreted by white blood cells (or neutrophils) that digests
damaged and aging cells in addition to bacteria (5,25-28).
Following the standard serpin structure, the !1-Antitrypsin structure consists of
nine !-helices, 3 ß-sheets and a mobile reactive center loop. In its native active form,
the overall conformation is in a metastable state and it isn’t until the serpin is rendered
inactive (either through cleavage or latency) that the conformation is in the most energy
efficient state (5,25-29).
This section will go into more detail about the !1-Antitrypsin protein, with a focus
on its role in the body as well as its gene and protein structures.
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Figure 1.2 !1-Antitrypsin and Neuroserpin Polymers. !1-Antitrypsin and neuroserpin Intracellular inclusions identified
in hepatocytes and neurons with PAS staining (a and c, respectively) and endoplasmic aggregates of the abnormal
proteins on electron microscopy (b and d, respectively). Histology of neurosperin inclusions post-mortem for Ser49Pro (e),
Ser52Arg (f), and Gly329Glu (g) mutations. Adapted from (5,6,20)
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Figure 1.3 Cellular Responses to Serpin Polymers. Correctly folded (native) proteins are packaged into ER-to-Golgi
transport vehicles for secretion (not shown), whereas misfolded monomer and folding intermediates are targeted by the
ERAD. Some misfolded monomers are able to form dimer or polymers and form inclusion bodies with the ER.
Accumulation of these inclusion bodies can cause an increase in cytosolic Ca2+ and eventually the activation of the NF-"B
pathway. Taken from (5).
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b) What is Alpha1 -Antitrypsin?
First identified as part of a clinical disease in 1963, by Laurell and Eriksson (30),
Alpha1-Antitrypsin (AAT) is one of the most studied serpins today. AAT is an acute
phase glycoprotein that is mainly synthesized in the liver and then secreted into the
bloodstream, where its normal plasma concentration is around 1.5g/L. This can almost
double during inflammation. In addition to hepatocytes, AAT can also be synthesized by
macrophages and intestinal and bronchial epithelial cells. The main function of AAT is to
protect tissues from the serine protease, neutrophil elastase (NE), but it also been
shown to inhibit trypsin, cathepsin G and proteinase 3 (5,25-28).
Role in the Body
Once in the bloodstream, AAT travels to the lower tracheal region where it
protects the alveolar tissue from proteolytic activity and damage produced by neutrophil
elastase (NE). This protease is one of three packed within azurophil granules used by
neutrophils to break down elastin and other extracelluar matrix components. The ability
to break down most matrix proteins is especially helpful when neutrophils need to
migrate through such matrixes in order to get to the main site of infection (31,32).
However this also has the potential to be very harmful. For example, when AAT plasma
levels get too low and there is not enough AAT available to protect the lungs, NE will
start to degrade the healthy lung tissue in addition to its normal targets. This can lead to
the onset of emphysema or other forms of COPD (5,25-28). The necessary balance
between protease, NE, and anti-protease, AAT, lead to the proteinase-antiproteinase
hypothesis over 40 years ago (27).
15

Gene Structure
The AAT gene is located on the long arm of Chromosome 14 (position q31-31.2)
and contains 7 exons (5,27,28). One thing that is interesting about its location is that
within 200kb of the AAT gene are two homologous DNA sequences, one coding for !1antichymotrypsin and the other for a psuedogene. Within the AAT gene itself are two
tissue-specific promoter regions, one for monocytes and one for hepatocytes.
Messenger RNA (mRNA) produced by monocytes differ form hepatocyte mRNA in that
the former contains 1-2 more exons than the later. The additional exons more than
likely account for differences in mRNA expression levels between the two sources
(monocytes express about 1% of the amount that hepatocytes do) as well as influence
the rate at which the AAT is translated (28).
Protein Structure
With 394 amino acids and a molecular weight of approximately 54KD, AAT is a
highly ordered and large globular polypeptide that is N-glycosylated at positions Asn46,
Asn83 and Asn247. This glycosylation is heterogenous, with Asn83 sometimes having
two or three N-glycans attached (28,33-35).
Keeping in line with the conserved serpin structure, AAT’s structure consists of
nine !-helices (A-I), three "-pleated sheets (A-C), and a Reactive Center Loop (RCL)
(5,25-29). During AAT’s active form, the RCL is thought to be intrinsically disordered;
however as soon as the protease forms a Michaelis complex with AAT, the RCL is cut
at Met358 and Ser359 (referred to as P1 and P1’ respectively) (28). Once this happens,
the P1’ residue is released and an ester bond is formed between AAT and the protease.
The protease is then flipped from the upper pole of AAT to the lower pole, causing the
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RCL to be inserted as an extra strand (s4A) into the central "-sheet A (5,25-29). This
conformational change is very stable and acts as a signal to the cell that the protease is
ready for destruction and is taken away, as illustrated earlier in this chapter.

1.3 Alpha1-Antitrypsin Deficiency
a) Overview
Alpha1-Antitrypsin Deficiency is an often-misdiagnosed yet increasingly common
genetic disease that is associated with both liver and lung disease and is thought to
have a frequency comparable to cystic fibrosis (28,36). In the fifty years since Laurrel
and Eriksson “discovered” it as a clinical disease (30), studies have shown that certain
mutations in the serpin !1-Antitrypsin can cause it to misfold and form polymers. While
it is believed that this polymerization process is the underlying cause for Alpha1Antitrypsin Deficiency, the exact mechanism in which this occurs is still unknown. In this
section we will discuss what exactly Alpha1-Antitrypsin Deficiency is, including what
causes it and how it is currently being treated today.

b) What is Alpha1-Antitrypsin Deficiency?
While Alpha1-Antitrypsin Deficiency was reported in an Alaskan girl who died 800
years ago (37) and it may have been responsible for the premature death of Fredric
Chopin in 1849 (38,39), it wasn’t until 1963 that it was first describe as a clinical
disease. It was at this time that Carl-Bertil Laurell and Sten Eriksson first observed the
absence of the !1 protein band in plasma taken from two patients in a respiratorydisease hospital. This absence was later linked to a deficiency in the !1-Antitrypsin
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protein. It was this connection that not only helped to reveal an underlying mechanism
for emphysema but also introduced scientists to a whole new family of proteins, the
serpins (27,40).
As discussed previously, serpins are prone to mutations that lead to
polymerization (Section 1.1c) and AAT is no exception to this phenomenon. In fact, the
polymerization of AAT has been linked with the conformational disease, Alpha1antritrypsin deficiency (AATD), and can result not only in the development of chronic
obstructive pulmonary disease (COPD) but also hepatitis, cirrhosis and even
hepatocellular carcinoma (Figure 1.4) (36,41). AATD has been shown to affect people
of virtually all ages, populations and ethnic groups. In fact it is estimated that there are
of approximately 116 million carriers and 1.1 million patients with severe AATD
worldwide, indicating that the disease is probably one of the most common severe
hereditary disorders in the world (42).
Clinical Manifestations
AATD can manifest itself clinically though both pulmonary and hepatic
manifestations, although these may vary widely from patient to patient, with both rarely
seen in the same patient (43). The dominant manifestation is in lung disease, which
begins in early adulthood, and can develop sooner if additional risks are present (e.g.
tobacco smoking or occupational air pollutants). Severe lung impairment, such as
COPD and emphysema, are predicted to manifest when AAT serum concentration falls
below the protective threshold of 35% the normal mean value (# 0.8g/L) (43). In addition
to low AAT serum levels, it is also thought that AAT polymers themselves may promote
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inflammatory processes in the lung. This increases the amount of NE present in the
lungs and further contributes to the accelerated destruction of lung tissue (36,43,44).
While AATD is one of the most frequent causes of liver cirrhosis (after viral
hepatitis, alcohol abuse, and chronic cholangitis), adults with AATD-related genotypes
develop liver disease less frequently than lung disease. The progression of liver disease
in AATD patients appears to be slow and typically manifests first as hepatitis (swelling
and inflammation of the liver) before developing into fibrosis or cirrhosis. It has also
been reported that there is a relatively higher prevalence of hepatocellular carcinoma
and cholangiocellular carcinoma associated with AATD than with other hepatic diseases
(36,43).

Neonatal hepatitis syndrome with cholestais (bile blockage) occurs in a small

percentage of newborns that are homozygous for deficiency AATD genotypes. Prolong
jaundice after birth with conjugated hyperbilirubinemia (bilirubin concentrations greater
than 2mg/dL (45)) are classic clinical signs of this genotype, although the jaundice may
resolve itself spontaneously after a few weeks (36,43).
In rare occasions, AATD has been associated with the skin disorder panniculitis,
Wegener’s granulomatosis (antiproteinase-3-associated vasculitis), and aneurysms of
the abdominal aorta and brain arteries (36,43).

c) What causes Alpha1-Antitrypsin Deficiency?
As discussed in Section1.2b, the major function of AAT in the body is to regulate
NE activity. However when AAT levels are low, NE activity is left unchecked, allowing it
to digest healthy lung tissue in addition to its normal target.
emphysema and COPD, two disease associated with AATD.
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This can result in

Figure 1.4 The Effects of Alpha1-Antitrypsin Deficiency (46).

20

Typically a decrease in AAT levels is due to a Z point mutation (E342K) that
disrupts a salt-bridge within the structure. When this occurs, the protein misfolds, and
forms polymers that accumulate and create inclusion bodies inside the endoplasmic
reticulum of hepatocytes where it is produced. With the AAT protein trapped in the liver,
it cannot travel to the lungs and therefore cannot protect the lung tissue from damage
produced by NE. In addition, the polymers located in the liver can also lead to the
destruction of the hepatocytes themselves, therefore leading to diseases such as
cirrhosis and hepatitis (5,25-29).
Common mutations and their effect
Among the over 75 different variants of AAT (5), there is a small percentage of
variants that negatively affect AAT’s structure (Table 1.3). Of these, the Z variant is the
most common severe mutation and accounts for 95% of all cases of AATD (47,48). The
change from a glutamic acid to a lysine at residue 342 not only disrupts a salt bridge
that is normally present between K290 and E342, leading to the misfolding and
polymerization of the protein (28,47,48), but it may also be responsible for the failure of
the protein to be secreted (28). The plasma levels in the MZ heterozygote are 60% of
normal levels (normal levels are 1.4-3.5 g/L) whereas the ZZ homozygote has only 10%
of the normal (M) plasma levels (27). The low levels of plasma AAT are because over
80% of the ZZ homozygote protein are not secreted but polymerize and accumulate as
inclusions in the rough ER of the liver (29). As such, ZZ homozygotes also have a
reduced life span in which they have a 52% chance of being alive at age 50 and a 16%
chance at age 60 (normal is 93% and 85% respectively). Smoking further reduces this
by 10 years (28). The Z mutation is most prevalent in Northern and Western Europe
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with the highest concentration in southern Scandinavia, Denmark, the Netherlands, the
United Kingdom and northern France (36,49).
Another common mutation is the S variant (E264V), which is located in the
shutter region and reduces plasma AAT concentrations by 40% in homozygotes. While
the S variant alone is not affiliated with clinical disease, when it is co-inherited with the Z
variant, the two can interact to form heteropolymers within hepatocytes which then
develope into inclusions bodies and eventually cirrhosis (27,50). One explanation for
the lack of associated disease in homozygous S carriers is that this genotype produces
unstable AAT protein that can easily be degraded outside the hepatocyte, which in turn
affects its half-life (36). Unlike the Z variant, the S variant is most prevalent in Southern
Europe with the highest frequency in the Iberian Peninsula (36,49).
Some other mutations that can lead to AATD include the Siiyama variant (S53F),
the Mmalton variant (!52F), and the I variant (R39C). The Siiyama variant is the most
common cause of AATD in Japan whereas the Mmalton (also known as Mnichinan and
Mcagliari) variant is the main cause of AATD in the isolated island of Sardinia. Both of
these mutations destabilize the ß-sheet A in the shutter region, causing it to form
unfolded intermediates and polymers in vivo (6,8,27,41). The I variant also affects the
shutter region, but does so at a lesser extent. This causes polymer formation to be
slowed (when compared to Z polymers) which in turn result in reduced protein retention
in hepatocytes, milder plasma deficiency and lack of clinical disease. However, like the
S variant, a co-inheritance with the Z variant can lead to liver disease such as cirrhosis
(6,8,27,41).
Polymerization Mechanisms
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While it is well recognized that the polymerization of AAT is the underlying cause
of AATD, the exact mechanism of this polymerization phenomenon is unknown. Three
different models have been present over the years that strive to answer this question: 1)
s4A linkage 2) s4A/s5A domain swapping and 3) C-terminal swapping (Figure 1.5).
However in order to fully understand what these models are proposing, it is important to
look at what is currently known about the folding pathway of AAT.
Studies focusing on the unfolding and folding patterns of AAT go back over 20
years. In these initial studies, three species --native (N), unfolded (U) and intermediate
(I)—were identified during the unfolding process (47,51). This was shown to be true for
both the normal (M) and polymerization-prone (Z) forms of AAT. While both MAAT and
ZAAT transitioned from the U to I state at similar rates, they differed in their ability to
perform the final step of folding, I!N. It was revealed that ZAAT folding from the
intermediate state was significantly slowed, and it was this accumulation of I that
resulted in polymerization (47). The structure of the intermediate state, more commonly
referred as the polymerogenic monomer M*, has been debated greatly and is the basis
for differences seen in the three polymerization models.

23

S, E264V

Mmalton, !52F

Siiyama, S53F

Z, E342K

Variant,
Mutation

+

+

+++

+++

+++

Polymerization
Tendency

Normal levels
(1.4-3.5 g/L)

Mild
(extrapolation from levels
in heterozygotes)

Moderate
(60% of normal levels in
homozygotes)

Severe

Severe

Severe
(10-15% of normal levels)

Circulating Deficiency in
Homozygotes

No, although heterozygotes
can, on rare occasion, develop
clinical symptoms

Case report in IZ AAT
heterozygote

Reported in SZ AAT
compound heterozygotes

Yes

Yes

Yes in homozygotes, with less
hepatocyte inclusion bodies
present in heterozygotes (no
clinical disease associated)

Association with Clinically
Significant Liver Disease

95% of individuals are
homozygotes. Wild-type
AAT phenotype

Only reported in compound
heterozygotes

1 out of 5 Europeans are
heterozygotes. Most
common deficiency variant.

Most common severe variant
in Sardinian populations

Most common severe
variant in Japanese
populations

1 in out of 27 North
European heterozygotes.
Most common severe
deficiency variant.

Epidemiology

Table 1.3 Common !1-Antitrypsin Variations (Compiled from (36,41))

I, R38C

-

M
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For the longest time, the s4A linkage hypothesis was the accepted mechanism
for serpin polymerization, and was not challenge until just recently. This hypothesis is
based on the fact that the Z mutation is located on the head of strand 5 of !-sheet A at
the base of the RCL (also referred to as the s4A), causing !-sheet A to open and
transition to an unstable polymerogenic M* intermediate (26,52,53). The expansion of
upper !-sheet A allows the s4A position to be opened, allowing the RCL residues to
partially insert, releasing the first strand of !-sheet C (s1C) and partial uncoiling of helix
F. Next, the lower part of !-sheet A is expanded, allowing helix F to regain its shape
and opening the molecule to accept the RCL from another molecule, thereby forming a
chain of loop-sheet polymers (Figure 1.5) (5,53). This hypothesis has been supported
by extensive biochemical and biophysical analyses.
Nevertheless, in 2008, this model was challenged when Yamasaki and
colleagues presented a model in which the fourth and fifth strand of !-sheet A (s4A and
s5A respectively) of one molecule donates itself to another molecule in order to
complete the formation of the second molecule (referred to here as s4A/s5A domain
swapping, Figure 1.5). This model was based on the crystal structure of a selfterminating antithrombin dimer formed in the presence of the denaturant guanidine
hydrochloride (54). The physiological relevance of the s4A/s5A domain swap model was
brought into question however, when extensive studies by the Lomas group indicated
that only heat-induced polymers are able to correctly mimic those found in hepatocytes
(55). This was based largely on the identification and characterization of the 2C1
antibody, which was shown to identify AAT polymers both in vitro and in vivo (56).
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Figure 1.5 Alpha1-Antitrypsin Structure and Its Three Polymerization Models (57).
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Based on this, in 2011, Yamasaki and colleagues set out to determine the
structure of the heat-induced polymers, the result of which produced a third model of
polymerization. In this newest model, the C-terminal swap (Figure 1.5), monomers are
linked together via domain swapping that involves the carboxyl (C-) terminus of protein,
specifically s1C and strand 4 and 5 from ß-sheet B (s4B and s5B respectively).
Polymers produced in this study were shown to bind to the 2C1 antibody and were
obtained by heating recombinant protein at 60ºC (58).
It should be noted that the C-term swap polymers were not the only kind present
among those analyzed in this study. In fact, the heat-induced polymers contained a
mixture of both the s4A/s5A polymers and the C-terminal polymers. This polymer
heterogeneity could have important implications in regards to understanding AATD and
the development of therapeutics. In addition, it suggests the possibility of more than one
polymer structure being present simultaneously and raises the question of if toxic and
non-toxic polymers can coexist (57,58). Therefore more research is needed in order to
fully understand the types and effects of polymerization in AATD.

d) How is Alpha1-Antitrypsin Deficiency currently treated?
People who suffer from AATD (commonly referred to as Alphas) are very limited
in their options for treatment (59). For example, the most common treatment for endstage lung and liver disease is organ transplantation. Another popular therapy for
Alphas is intravenous augmentation of pooled plasma purified AAT, however this
process is very costly and often involves weekly treatments (36,43,46,59,60). In the
scientific community it is widely thought that more effective forms of treatments lie in the
attenuation of the polymerization process itself. There are currently three main
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strategies being developed that address this issue: 1) use of chemical chaperones, 2)
use of RCL peptides analogues and 3) targeting a surface cavity within the structure
(5,41,61).
The ability of chemical chaperones to help stabilize intermediates along the
folding pathway have been supported by studies where osmolytes such as
trimethylamine oxide, betaine and sarcosine were able to stabilize AAT against
polymerization (62). Chemical chaperones were also shown to be effective in cell and
animal models for disease (63-65), but failed to show any significant improvement in
clinical trials (66). In addition, since chemical chaperones promote protein folding, there
lies a risk that it may promote ZAAT to their lowest energy state, i.e polymers (41).
The second approach involves using RCL peptide analogues to compete for
binding to ß-sheet A and therefore block polymerization. This is founded on a study that
showed an antrithrombin RCL peptide was able to readily insert into the ß-sheet A of
AAT, and vice versa (14).

While helpful in understanding the polymerization

mechanism, the peptides proved to be too large and promiscuous for drug design (5).
To compensate, several groups have designed smaller peptides that end polymerization
by specifically annealing to the lower part of ß-sheet A (41,67). More research is
needed on these peptides before they are ready for therapeutic application.
Lastly, the third approach also uses a structural drug design approach but
instead of using peptides to target the RCL, it uses small molecules to block
polymerization by filling a surface hydrophobic pocket in AAT. The hydrophobic pocket
is surrounded by strand 2A and helices D and E and can be used for allosteric blockade
of the conformational transition that underlies polymerization (5,41,61). The pocket is
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unobstructed in the native protein but is filled as ß-sheet A accepts the RCL from
another molecule. When this pocket was partially filled by mutagenesis (Thr114Phe),
scientists saw a 10-fold reduction of polymerization and an increased ZAAT secretion in
a Xenopus oocyte expression system (68). This has led to use of in silico experiments
to identify small drug-like molecules that are able to target this pocket and inhibit
polymerization (5,41,61).

1.4 Expression of Recombinant Protein
a) Overview
The practice of using different model systems as a vessel to produce
heterologous proteins is a very common methodology in both industry and academia.
Recombinant proteins have not only been used as tools for cellular and molecular
biology but they can also be used as pharmaceuticals and vaccines (69,70).
Not only are recombinant proteins diverse in their applications but they also vary
greatly in the way they are produced. Several expression systems are currently
available today, which range from the microbial to the mammalian. These systems not
only differ in the time, ease and cost of expression but also in the size of protein they
are able to produce and the posttranslational processing that can be performed. This
section will look at a select few of the systems available today and will discuss the pros
and cons of each.
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b) Bacteria
Although many different types of prokaryotes have been used for recombinant
protein expression, the most common one by far is the Gram-negative bacterium,
Escherichia coli. Some other popular bacterial systems include Ralstonia eutropha,
Pseudomonas fluorescens, Staphylococcus carnosus, and certain Bacill strains (70,71).
Out of the expression systems discussed in this section, bacterial systems have the
lowest costs and the highest yields of protein (72).
Escherichia coli
E. coli was one of the first organisms used for heterologous human protein
production and is one of the most common hosts used today (71). For these reasons, E.
coli is on of the most well understood microorganisms with a vast amount of knowledge
known regarding its molecular biology, biochemistry and physiology (69). There are
several advantages of using E. coli as an expression system, including ease of culture,
high product yields, and rapid growth and expression. In fact E. coli, can be grown to
very high densities (over 100g/L) and requires a very simple nutritional regiment.
However when E. coli is grown at too high of densities, it can result in toxicity due to
acetate formation. Luckily this can be avoided by controlling the oxygen levels of the E.
coli culture (70). Another advantage of using E. coli is that its genome can easily be
manipulated in a short amount of time and with high precision. This can be very useful
in the transformation process and allows the plasmid copy number to be quickly altered.
E. coli is also able to thrive under several different environmental conditions and can
produce recombinant proteins up to 80% of its dry cell weight (70).
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In spite of all the advantages in using E. coli, there are

also several

disadvantages. One such disadvantage is E. coli’s inability to perform posttranslational
modifications (PTM), particularly glycosylation, which can affect protein stability,
solubility, folding, biological activity, localization, and circulation half-life (69). In addition
proteolytic cleavage and disulfide bond formation rarely occur (69) and refolding of
these proteins is extraordinarily difficult (70). The formation of inclusion bodies filled with
inactive, aggregated and insoluble protein is also a common issue and often requires
the refolding of the protein of interest. While yields are typically higher when produced in
the cytoplasm, proteins can also be secreted into the periplasmic space, which can help
with disulfide formation and reduction in inclusion bodies (70,71). Additional
characteristics of this system can be found in Table 1.4.
Other Bacteria
Secondary to the E. coli system, Gram-positive Bacilli strains are one of the most
popular bacterial expression systems for recombinant proteins (71). Like E. coli, Bacilli
are easily manipulated and are genetically well-characterized systems. The bacillus
system also displays strong secretion with no involvement of intracellular inclusion
bodies and has highly developed transformation and gene replacement technologies
already in place (70). Some commonly used species include Bacillus magaterium,
Bacillus subtilis, Bacillus brevis and Bacillus licheniformis (70,71). One particular
advantage of the Bacillus system is that members do not have lipopolysaccharidecontaining outer membranes like Gram-negative bacteria do, thereby eliminating the
extra step of endotoxin removal normally necessary in the later (70,71).
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Pseudomonas fluorescens, and Staphylococcus carnosus. R. eutropha is a Gramnegative bacterium that, with respect to inclusion body formation, appears to be better
than E. coli (73,74). In fact, organophosphohydrolase, a protein that typically is prone to
inclusion body formation, was produced at 10g/L in R. eutropha, compared to E. coli
where it is normally produced at less than 100mg/L (74). A P. fluorescens-based
platform, referred to as the Pfenex Expression TechnologyTM , has recently emerged
with high quality profiles and yields that sometimes can be more than 20g/L (75). S.
carnosus, was shown to produce and secrete a mammalian protein at 2g/L compared to
Streptomyces lvidans which was only able to express 0.2g/L (70).

c) Yeasts
Humans have used yeasts, the single-cell eukaryotic organisms, since the
Neolithic age. While originally used to produce food and beverages (76), yeasts
nowadays are used for multiple applications including heterologous protein production.
In fact, they are the most common choice for the expression of recombinant proteins
that are not successfully produced in E. coli due to improper folding or lack of
glycosylation (70). While slightly more expensive then bacterial systems, yeast systems
are still a relatively cost-efficient and simple expression system for recombinant proteins
(Table 1.4) (72). The two most used yeast species are Saccharomyces cerevisiae and
Pichia pastoris.
Saccharomyces cerevisiae
S. cerevisiae was first manipulated for recombinant protein expression use in
1987, when it was used to express human insulin (77). Since then, countless more
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proteins have been expressed in this yeast species. Due to its history and its many
applications, the molecular biology and physiology of S. cerevisiae has been extensively
researched and accumulated (69).
S. cerevisiae has many advantages over E. coli as an expression system, some
of which include its long history of fermentation, ability to secrete proteins into the media
and the glycosylation of proteins. Since S. cerevisiae naturally secretes very few
proteins, the secretion of heterologous proteins acts as a first step in purification,
thereby reducing the time needed to purify the protein of interest. Glycosylation by S.
cerevisiae, however is often intolerable for mammalian cells due to differences in their
O-linked oligosaccharides and the fact that S. cerevisiae has a tendency to over
glycosylate N-linked sites (70). Since glycosylation is species-tissue- and cell-typespecific and necessary for protein stability, solubility, folding, biological activity,
localization, and circulation half-life, this issue could drastically affect the usability of
certain proteins downstream (69).
Pichia pastoris
With cell densities as high as 130g/L and protein concentrations up to 10g/L, the
methylotrophic yeast, Pichia pastoris has quickly emerged as a powerful yeast
alternative to S. cerevisiae (69,70). Some additional advantages of P. pastoris over S.
cerevisiae are avoidance of hyper-glycosylation, growth in high methanol solutions, and
integration into chromosomal DNA (70). By far, the greatest advantage of using P.
pastoris is the fact that it is capable of producing disulfide bonds and glycosylation of
proteins. Unlike S. cerevisiae, N-glycosylation in P. pastoris is less complex and occurs
less often (69).
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As a methylotrophic yeast, P. pastoris is able to metabolize methanol as its sole
carbon source, allowing it to grow in high methanol solutions that would normally kill
other microorganisms (70). In addition, the AOX1 promoter, which regulates the AOX1
gene that expresses the alcohol oxidase (AOX) enzyme needed to utilize methanol, is
often used as a promoter in the over-expression of recombinant protein genes
introduced via a Pichia expression vector (78,79). When grown on glucose, glycerol or
ethanol, AOX expression is undetectable in Pichia cells, however when they are
switched to a methanol solution, expression is dramatically increased. This allows
scientists to easily control the expression of heterologous proteins by simply switching
the media (80,81). However, care should be taken when using methanol, since it is a
flammable reagent and is toxic to humans (69). Lastly, many of the techniques needed
for molecular genetic manipulation in S. cerevisiae, can also be used in P. pastoris
thereby making P. pastoris an easily manipulated, user-friendly, heterologous protein
producing machine (80,81).

d) Insect Cells
A common alternative to using a yeast system for recombinant protein production
is to use insect cells (72). Insect cells are able to carry out more complex PTMs than
those produced by yeasts and also have one of the best folding machineries for
mammalian proteins (70,82). Instead of a plasmid vector, insect cells are commonly
infected with baculoviruses that contain relatively large, double-stranded circular DNA
genomes. The most common baculovirus used is the Autographa californica multicapsid
nucleopolyhedrovirus (AcMNPV) that is easy to culture and is able to infect
approximately 25 different lepidopteran insects (i.e. moth and butterflies), giving it a
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broad host range compared to other baculoviruses (70,83). The most common host is
the fall armyworm (Spodoptera frugiperda), which in larvae form can be a lot cheaper
than mammalian cell cultures (70).
There are several advantages to using the baculovirus- infected insect cells for
recombinant protein production. As stated before, this system is able to carry out more
complex PTMs which include phosphorylation, correct signal peptide cleavage,
acylation, N- and O-glycosylation, and proper proteolytic processing, among others
(70,84,85). In addition, insect cells are able to properly fold proteins and allow for
disulfide formation. Other advantages include no limit on protein size, ability to express
multiple genes at once (86), and high expression levels and possible yields of 11g/L
(70). Since the baculoviruses used to infect the insect cells are only able to attack
invertebrates and not vertebrates, an added layer of safety is added overall to the
system (70).
As with any system, there are some disadvantages in using the insect cell
system for heterologous protein production. Expression is often very time-consuming,
especially when compared to bacterial systems. In addition, protein yields can vary as a
result of several different variables including cell culture medium, virus titer, and
expression time after infection (87). While insect cells are able to glycosylate proteins,
there have been reports in which this has occurred incorrectly. Compared to the
different glycoforms present in mammalian cells, potential N-glycosylation sites for
proteins produced in insects are typically either fully glycosylated or not glycosylated at
all (70). Additional characteristics of the insect cell system are shown in Table 1.4.
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e) Mammalian Cells
Over the past two decades, mammalian cells (Table 1.4) have become one of
the dominant systems for recombinant protein production, especially for proteins that
require mammalian glycosylation or are not folded correctly in other systems (88). The
most frequently used mammalian cell lines are Chinese hamster ovary (CHO) and
COS-7 cells [derived from CV-1 (simian) cells in origin and carry the SV40 genetic
material] (89). Other popular cell lines include mouse myelomas (NS0 and SP2/0),
human embryonic kidney (HEK-293) cells and baby hamster kidney (BHK-21) cells
(70,88,90).
One of the major benefits of using mammalian cells is that the proteins they
produce are properly folded and glycosylated, thereby removing the need for protein
refolding. Aside from glycosylation, mammalian cells can also add fatty acid chains, and
phosphorylate Tyr, Thr and Ser hydroxyl groups on heterologous proteins (70). Another
benefit of the mammalian system is their high productivity of 20-60pg/cell/day with some
protein titers even producing as much as 10g/L in a industry setting (70). In addition,
foreign DNA can be inserted into the nucleus of mammalian cells in a multitude of ways
including calcium phosphate, electroporation, coprecipitation, lentiviral transduction, and
transfection with lipofectamine and other chemical reagents (89).
There are a few disadvantages to using the mammalian cell system. To begin
with, mammalian processes are very expensive (especially the media which requires
the addition of hormones and growth factor) and are very time-consuming. Mammalian
cells are also prone to contamination from viruses or prions, which ultimately adds to
the cost of production, and are very poor at being able to secrete proteins (70).
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Table 1.4 Characteristics of the Different Recombinant Protein Expression Systems Discussed in this Chapter.
(Taken from (72))

Rapid (90 min)
Minimum

High

Slow (18-24 hr)
Complex

Low-Moderate
Secretion to Medium

High

Slow (24 hr)
Complex

Mammalian Cells

Rapid (30 min)
Minimum
Low

Low-High
Secretion to Medium

Proper Folding

Insect Cells

Low
Low-High
Secretion to Medium

Proper Folding

Complex
Yes
Yes
Yes
Yes
Yes
0.1-100

Yeast

Cell Growth
Complexity of
Growth Medium
Cost of Growth Medium
High
Secretion to Periplasm

Refolding May Be Required

Simple, No Sialic Acid
Yes
Yes
Yes
Yes
No
10-200

80-95

E. coli

Expression Level
Extracellular Expression

High Mannose
Yes
Yes
Yes
Yes
No
10-200

50-70

Characteristics

Protein Folding

Refolding Usually
Required
None
No
No
No
No
No
50-500
50-70

High
Functional study, PTM
study, Assay standards,
characterization

40-60

N-linked Glycosylation
O-linked Glycosylation
Phosphorylation
Acetylation
Acylation
gamma-Carboxylation
Yield (mg)
(per liter culture)
Success Rate (%)
(Soluble of Functional)
Project Cost
Recommended Use
Low
Antigen protein,
Protein standards,
functional proteins

Low
Proteins with glycosylation,
Vaccine, Secreted form,
Alternative to insect cell
system

Advantage

Simple, low cost, good for
certain proteins
Longer time, less PTM

Natural protein
configuration, best PTM
Highest cost, lower yield

Simple, robust, lowest
cost, highest yield
Least PTM

Middle
Proteins with
glycosylation, Assay
standards, Secreted form,
Alternative to yeast
system
Relatively higher yield,
better PTM
Longer time, higher cost

Disadvantage
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CHAPTER 2:
PROJECT RATIONALE AND SUMMARY

Alpha1-Antitrypsin Deficiency is an autosomal recessive disorder that can
manifest clinically as liver cirrhosis, emphysema and, on rare occasions, as the skin
disease panniculitis (27,36,61). The onset of this disorder has been linked to mutations
in the archetype serpin, !1-Antitrypsin (AAT), that cause it to misfold and polymerize.
AAT is an acute phase glycoprotein that is primarily synthesized in the liver and
then secreted into the bloodstream. Once in the bloodstream, AAT travels to the lower
tracheal region where it protects the alveolar tissue from neutrophil elastase, a serine
protease that aids in the digestion of bacteria as well as damaged and aging cells
(27,31,32,36,41,43,50,61,91).
However when levels of AAT are low, neutrophil elastase will digest healthy lung
tissue as well. Typically this decrease in AAT levels is due to a point mutation, referred
as the Z variant (E342K), that disrupts a salt-bridge within the structure and causes the
protein to misfold. These misfolded proteins can then form polymers that accumulate
and create inclusion bodies inside the endoplasmic reticulum of hepatocytes
(27,36,41,43,50,61,91). This reduction in available AAT causes a two-fold effect: 1)
uncontrolled activity of neutrophil elastase increases the likelihood of emphysema or
other chronic obstructive pulmonary diseases developing, and 2) accumulation of AAT
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polymers can destroy hepatocytes leading to the on-set of liver diseases, such as
cirrhosis and hepatitis (5,25-29).
Current treatments for Alpha1-Antyrpsin Deficiency (AATD) are very limited, the
most common of which is substitution therapy with human AAT protein. This method is
often very time consuming, requiring weekly intravenous treatments of protein derived
from pooled human plasma, and can be very costly (43). Instead of treatments that add
AAT proteins to reverse the effects of AATD, most researchers today believe that more
efficient and cost-effective treatments will be found by concentrating on the disruption of
AAT polymerization. However, even after over twenty years of research on AAT, the
exact molecular basis of this polymerization is still unclear. Therefore, in order to find a
treatment for AATD, additional research is needed to further understand the
polymerization mechanism of AAT.
Most polymerization studies today use AAT protein that has been purified from
the plasma of affected patients. The amount of protein acquired using this method is
very limited however, making it difficult to perform more in-depth studies on the
polymerization mechanism. The ability to produce recombinant AAT protein, on the
other hand, could provide a safer alternative to obtain needed protein concentrations.
Since the first recombinant AAT (wild-type, M) was purified from yeast in 1985
(92), numerous expression systems have been used to produce MAAT protein
(35,89,93-99). However the Z variant of AAT, with its tendency to polymerize, has long
thwarted any attempts at heterologous production. In 2009, a published study indicated
the first successful attempt at producing recombinant ZAAT protein (100). This study,
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which used Pichia pastoris to produce tagged ZAAT protein, paved the way to an
unlimited source of AAT protein.
The goal of this thesis research was to build upon the 2009 paper in order to
produce copious amounts of protein that could be used for future experiments focusing
on Z !1-Antitrypsin polymerization. In particular, this thesis discusses the attempts made
at producing both tagged and untagged versions of recombinant ZAAT protein using
Pichia pastoris. While the successfulness of the methods implemented during this thesis
work remains to be determined, they did provide foundational information that can be
used in future endeavors. As is, several modifications and optimizations would need to
occur before this methodology could be deemed profitable. Suggestions of what these
might include are discussed throughout the thesis.
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CHAPTER 3:
EXPRESSION AND PURIFICATION OF
UNTAGGED !1-ANTITRYPSIN PROTEINS

3.1 Introduction
As stated in Chapter 2, a paper was published in 2009 by Levina et al that
showed the Z variant of !1-antitrypsin (AAT) being successfully produced recombinantly
using the methylotrophic yeast, Pichia pastoris (100). Following the publication of this
research, it was decided that this procedure would be adopted in hopes of producing
active M (wild-type) and Z (mutant) forms of AAT. Unlike the paper however, which
added a Polyhistidine-tag to the N-terminal of the proteins, our proteins would lack any
sort of protein tag since it was feared they might interfere with our downstream
applications.
Additional alterations were made in terms of vector type, clone selection, as well
as induction and harvesting methods. This chapter will cover the different techniques
used in our attempt to produce untagged, properly folded, active AAT recombinant
protein using two strains of Pichia pastoris. The implementation of these techniques
helped to lay the groundwork for future attempts within our lab.
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3.2 DNA preparation
Before work could begin in Pichia pastoris, cDNA was first synthesized for both
the wild-type and mutant forms of !1-Antitrypsin and then ligated into a vector that was
suitable for expression in P. pastoris. This was conducted through a series of
experiments as described below.

a) AAT DNA Constructs and Vectors
Gene constructs for both the wild-type (MAAT) and mutant (ZAAT) forms of !1Antitrypsin were synthesized from the company BlueHeron Biotech (Table 3.1). The
DNA used was based on the FASTA sequence published on UniProt (Accession
#P01009, http://www.uniprot.org/) and was codon-optimized for expression in Pichia
pastoris. The sequences were flanked by BamH I and EcoR I restriction sites to aid with
integration into the pPic3.5K vector (Invitrogen) used for P. pastoris expression. It is
likely that ZAAT misfolds in the endoplasmic reticulum (ER) where it is targeted by the
ER-associated degradation (ERAD) pathway (5). For this reason, the signal peptide
sequence (amino acids 1-24) was removed from our constructs and our proteins were
produced in the cyotsol instead of being directed to the ER. Both the cytosol and the
ER have chaperones present to assist with folding, therefore no complications were
expected as result of this change in location (100). Lastly, the pPic3.5K vector is a
transcription fusion vector, which means it does not contain an AUG initiation codon for
translation of the open reading frame within the expressed insert (78). Therefore the
Kozak consensus sequence was added to the N-terminal of both sequences to ensure
that proper translation initiation of our genes occurred in P. pastoris.
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Table 3.1. Protein Sequences for MAAT and ZAAT. Sequences are based on cDNA generated from Blue Heron
Biotech. Restriction enzymes sites are depicted in blue, Kozak sequence for pPic 3.5K in green and Z mutation (E342K)
shown in red. Both proteins are predicted to have a molecular weight of approximately 45kDa and an isolectric point of
5.31 (www.expasy.org).

MAAT

GSTMEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLG
TKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYH
SEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFH
VDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENE
DRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGA
MFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK-EF

Protein Sequence

ZAAT

GSTMEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLG
TKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYH
SEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFH
VDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENE
DRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDKKGTEAAGA
MFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK-EF
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Both constructs were synthesized into the Blue Heron pUCminusMCS vector, a
3.2kb plasmid that lacks a multiple cloning site and carries an ampicillin-resistance gene
(AmpR, Figure 3.1). The AmpR gene can be used to help with selection, replication and
maintenance in E. coli. However, since pUCminusMCS is not compatible for expression
in P. pastoris, it was necessary to first insert the DNA into E. coli so that it could be
easily manipulated and then transferred to the pPic3.5K vector. The pPic3.5K vector is
a 9kb vector that expresses genes intracellularly with multi-copy integrations (Figure
3.2). Using this vector, target genes can be integrated into the P. pastoris AOX1 locus
or the His4 locus (Figure 3.3). pPic3.5K also contains a bacterial Kanamycin-resistance
gene (KanR from Tn903) that confers resistance to the antibiotic G418 in P. pastoris and
kanamycin-resistance in E. coli (101,102). The KanR gene can be used to screen for
multicopy inserts by testing for increased G418 resistance following transformation. This
is different from the pHILD2 vector used in the Levina et al paper that could only screen
for transformants using the HIS4 marker.

In addition, the two vectors differ in the

number of unique sites available for gene ligation. The pHILD2 contains only one
unique EcoR I site for blunt-end cloning (103), whereas our pPic3.5K

vector has

multiple unique cloning sites available for directional cloning (102).

b) Subcloning of AAT cDNA into pPic3.5K
In order to transfer MAAT and ZAAT DNA into the appropriate vector, several
steps had to first be taken. These steps included bacterial transformation, plasmid
isolation, restriction enzyme digestion and finally ligation. Techniques used for each of
these steps are discussed below.
44

Figure 3.1 Blue Heron pUCminusMCS Vector used for DNA synthesis. (Taken from
Blue Heron (104)).

Figure 3.2 pPic3.5K Vector Map used for expression in Pichia pastoris. (Taken from
Invitrogen (102)).
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A)

B)

Figure 3.3 Gene Insertion in Pichia pastoris. Genes of interest can be inserted either
at the (A) HIS4 or (B) the AOX1 locus through homologous recombination.
Abbreviations: ORF, open reading frame; TT, transcriptional termination sequence (78).
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Bacterial transformation was used as a way to amplify the amount of available
cDNA: every time the transformed bacteria divided, the plasmid was also replicated
(105). Once enough bacteria cells were produced, the cDNA was harvested and then
used in the other subcloning steps. Both the MAAT and ZAAT constructs were
transformed into E. coli using Max Efficiency® DH5!™ Competent cells (Invitrogen),
with a stock pUC19 solution (0.01µg/mL) used as a control. To summarize, competent
cells that had been thawed on wet ice were aliquoted into pre-chilled 17 X 100mm
polypropylene tubes (Falcon® 2059) at 100µL per tube. Approximately 100ng of DNA
(MAAT or ZAAT) or 50pg of pUC19 were added to the cells and mixed by gently tapping
the tube. Cells were incubated on ice for 30 minutes and then heat-shocked in a water
bath at 42°C for 45 seconds. After a 2-minute incubation on ice, 0.9mL of room
temperature Super Optimal broth with Catabolite repression (SOC, Invitrogen) was
added to each tube and then shaken at 225rpm (37°C) for 1 hour (106).
Although DH5! is naturally susceptible to Ampicillin, both pUC19 and
pUCminusMCS contain the AmpR gene, which confers resistance to this antibiotic.
Therefore once transformation was complete and the cells had recovered in the SOC
media, they were streaked onto Luria Bertani (LB) agar plates with 100µg/mL Ampicillin.
This ensured that only properly transformed cells would be able to survive on the LB
plates. Prior to streaking, cells were diluted with SOC media at 1:100 (control) or 1:4,
1:10, and 1:20 (MAAT and ZAAT). Plates were then inverted and incubated overnight at
37°C.
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Viable colonies were picked the next day and used to inoculate larger cultures in
LB broth overnight. DNA was then isolated from these cultures using either the S.N.A.P.
Miniprep Kit (<5mL of culture) or the S.N.A.P. Midiprep (10-100mL of culture) Kit, as per
manufacture’s instructions (both of which were from Invitrogen).
Briefly, the bacterial cells were first pelleted and then resuspended in
resuspension buffer containing RNase A (50mM Tris-HCl, pH 8.0, 10mM EDTA). Next
the cells were lysed with Lysis Buffer (0.2M NaOH, 1% SDS) and then protein and
genomic DNA from the cells was precipitated using a precipitation salt (3M Potassium
acetate, pH 5.2). The lysate/precipitate was then filtered through a filtering column
(“Column A”), to which Binding Buffer (7.5M Guanidine-HCl) was added to the
flowthrough. This flowthrough was then applied to the binding column (“Column B”),
allowing the DNA to bind to the column and everything else to elute into the
flowthrough. The bound plasmid was then washed, first with 5M Guanidine-HCl, 50mM
MOPS, pH 7.0 and then with 400mM NaCl in 95% ethanol. After the washing was
complete, the resin was then dried by centrifugation and the DNA was eluted with sterile
Molecular Biology Grade water (107).
Once the DNA was isolated, restriction enzyme digestion was used to verify that
our DNA had been properly replicated and isolated from E. coli. In addition, restriction
enzyme digestion also allowed us to isolate MAAT and ZAAT cDNA from the
pUCminusMCS vector so that they could be transferred into the pPic3.5K vector.
Restriction enzyme digestion was performed for 1 hour at 37°C, and involved
treating the samples with either the BamH I restriction enzyme by itself (Figure 3.4A,
Lanes 2 and 4), BamH I with the EcoR I restriction enzyme (Figure 3.4A, Lanes 3 and
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5), or no enzymes at all (not shown). BamH I and EcoR I enzymes were both obtained
from Invitrogen. The products from the digest were separated by agarose gel
electrophoresis (1% agarose gel), visualized by ethidium bromide staining and then
photographed under UV light.
As shown in Figure 3.4A Lanes 2 and 4, a single band (~5kb) was observed after
digest with BamH I alone. This indicated that the DNA had been linearized but was still
fully integrated into the pUCminusMCS vector. Digestion with both EcoR I and Bam H I
resulted in two bands being separated via electrophoresis (Figure 3.4A, Lanes 3 and 5):
the top band (~3kb) being the pUCminusMCS vector and the bottom band (~1.2kb)
representing our gene of interest.
After the DNA was isolated through restriction enzyme digestion and
electrophoresed on the agarose gel, the gel piece containing MAAT or ZAAT DNA was
excised and purified using the S.N.A.P. Gel Purification Kit (Invitrogen), as per
manufacture’s instructions.
The newly isolated DNA was then ligated into the pPic3.5K vector following a
modified version of the T4 DNA Ligase (Invitrogen) protocol. Briefly the ligation reaction
consisted of five different treatments (Table 3.2) with a 3-to-1 insert-to-vector ratio and
was carried out overnight at 4°C. Products were then transformed into E. coli, and
plated onto LB agar plates with 100µg/mL Ampicillin as described previously.
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Figure 3.4 ! 1-Antitrypsin DNA manipulations in E. coli. Restriction Enzyme
Digestion of MAAT and ZAAT cDNA in the (A) pUCminusMCS vector and in the (B)
pPic35k vector, where pMAAT and pZAAT represents ligation into the pPic3.5K vector.
DNA linearization with (C) Sal I and (D) Sac I. Gels were made with 1% Agarose,
stained with ethidium bromide and photographed under UV light. Hyperladder I (Bioline)
was used for all DNA gels.
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Figure 3.4 continued.
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Table 3.2 Ligation Reaction Treatments. Treatments A and B were used as controls to verify
the necessity of both DNA’s for the reaction. Treatements D and E acted as controls for DNA
ligase activity. Set-up was based on protocol in Molecular cloning: a laboratory manual (108).

Treatment

DNA Present

DNA Ligase?

A

pPic3.5K

Yes

B

MAAT/ZAAT

Yes

C

pPic3.5K + MAAT/ZAAT

Yes

D

pPic3.5K

No

E

MAAT/ZAAT

No
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As expected, only plates that had treatment C (pPic3.5K + MAAT/ZAAT DNA in
the presence of the DNA ligase) streaked upon them showed any substantial E. coli
growth. Colonies from these plates were isolated and grown in an overnight culture of
LB Broth plus 100µg/mL Ampicillin. DNA from the overnight culture was then extracted
using the S.N.A.P.™ MidiPrep Kit and digested with restriction enzymes as described
previously. The double digestion with EcoR I and BamH I (Figure 3.4B) resulted once
more in two bands being identified via electrophoresis: the top band (~9kb) indicating
the pPic3.5K vector and the bottom band signifying our gene of interests (~1.2kb).
Once the success of the ligation was confirmed, the DNA was then linearized
overnight. This was done initially with the restriction enzyme Sac I (Promega), which
would allow the DNA to insert at the AOX1 locus (Figure 3.4C, Lanes 2 and 4), and then
later with Sal I (Promega), which inserts the DNA at HIS4 (Figure 3.4D). Both forms of
digestions resulted in bands at ~10kb after separation by electrophoresis. DNA clean-up
was performed afterwards using the Wizard® SV Gel and PCR clean-up System
(Promega), as per manufacture’s instructions

3.3 Expression in Pichia pastoris strains X33 and SMD1163
Initially two different strains of P. pastoris were used to express our recombinant
vectors: X33 and SMD1163. Both of these strains contain the AOX1 promoter, which
allows for rapid growth when methanol is utilized as the sole carbon source (methanol
utilization plus or Mut+ phenotype) (78-80).
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X33 is a wild-type strain that is a derivative of GS115, one of the most commonly
used strains of P. pastoris. Unlike GS115, however, the X33 strain has no defects in
histidinol dehydogenase activity encoded by the HIS4 gene (His+ phenotype)
(79,103,109). Due to the His+ phenotype of X33, selection in this strain is only possible
through antibiotic resistance conferred by the vectors that carry the gene of interest
(103). In our case, this means that selection for X33 clones was carried out based on its
resistance the antibiotic G418.
SMD1163 (his4, pep4, prb1), on the other hand, is a His! and protease-deficient
strain that lacks both the PEP4 and PRB1 genes. The PEP4 gene codes for proteinase
A, a vascular aspartyl protease that is essential for the activation of carboxypeptidase Y,
proteinase B, as well as other vacuolar proteases. Proteinase B can also be produced
as a result of PRB1 gene translation. Therefore, by eliminating these two genes, the
activity

levels

of

the

three

main

proteases

in

P.

pastoris

(proteinase

A,

carboxypeptidase Y, and proteinase B) are drastically reduced or even eliminated. This
can create a more suitable environment for expression of certain heterologous proteins
that are prone to protease degradation (78,80). Selection of SMD1163 clones can be
carried out either through selecting for His+ clones, selecting by its resistance to
antibiotics, or a combination of both, depending on the vector introduced into SMD1163.

a) Transformation into Pichia pastoris strains
While there are several different methods that can be used to transform foreign
DNA into P. pastoris, spheroplasting and electroporation tend to provide the highest
transformation efficiencies for most researchers (103 to 104 transformants/µg DNA)
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(110,111). However, spheroplasting, which involves the partial digestion of the yeast
cell wall by Zmolyase (110), can be a very tedious and time-consuming process.
Therefore, electroporation was implemented for the transformation of our P. pastoris
strains. Electroporation and initial selection of P. pastoris clones were performed as
described below with the help of Dr. Thomas Masi from the Biochemistry, Cellular and
Molecular Biology Department at the University of Tennessee in Knoxville, Tennessee.
Prior to electroporation, yeast cells were chemically pretreated with Lithium
acetate (LiAC) and dithiothreitol (DTT) according to the procedure outlined by Wu and
Letchworth in 2004 (111). The combination of LiAC with a reducing agent, such as DTT,
as a chemical pretreatment has been shown to increase the permeability of yeast cells
though an unknown mechanism. This results in an increase in transformation efficiency
by approximately 150-fold (111). Using this method, the cells (8x108 cells needed per
transformation) were made competent by first washing them with sterile water and then
suspending them in 100mM LiAC, 10mM DTT, 0.6 M Sorbitol, and 10mM Tris-HCl.
Making sure to keep the cells cold, they were then washed with 1M Sorbitol plus 10mM
Tris (pH 7.5) several times at increasing smaller volumes until there was approximately
1010 cells/mL in 80µL. Finally the cells were washed once more with sterile water in
order to remove all salts present (111). Sorbitol was used throughout the process in
order to stabilize osmotic pressure and to support the integrity of the yeast membrane
(112).
Once the yeast cells had been prepared, they were then mixed with 3ng of DNA
suspended in 1µL of water, and transferred into an ice-cold sterile electroporation
cuvette with a 0.2 cm electrode gap width. Next, they were incubated on ice for 5
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minutes and then placed into the MicroPulser Electroporator (BioRad). The lower
temperature prior to electroporation helps to decrease heat damage to the cells and can
increase transformation efficiency. The electroporation was conducted using the “Pic”
setting on the machine, with an average time around 5.8ms and voltage of 2.0KV.
Following electroporation, Sorbitol was used once more as osmotic support
during cell recovery. Cells were resuspended in Sorbitol and incubated at 30°C for one
hour. YEPD (Yeast extract, Peptone, and Dextrose) was then added to the cells so that
the Sorbitol and YEPD were in a 1:1 ratio and the cells were incubated at 30°C for
another hour.

After the second one-hour incubation was complete, 1mL of the

transformed cells was spread onto YEPD agar plates with 0.25mg/mL of G418, as
recommended by Invitrogen (102). The plates were then placed in an incubator at 30°C
and allowed to grow for 3-5 days. This temperature was used because it has been
found by researchers to be optimal for protein production in Pichia pastoris. Conversely
a temperature of 32°C has been shown to inhibit all protein expression (113). Therefore
for all of our growing conditions with P. pastoris, it was important to maintain the
temperature at 30°C.

b) In vivo Screening of Multiple Inserts
It has been previously shown that multiple-copy integrations of recombinant
genes in P. pastoris can result in increased expression of the desired gene
(101,114,115). Such integrations occur spontaneously at a low but detectable
frequency—between 1% and 10% in all His+ transformants. The pPic3.5K vector can be
used to generate and isolate multi-copy insertions through in vivo methods (78,102).
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Once the transformed clones had an adequate amount of time to recover and
grow, they were screened for multiple-copy integrations in one of three ways. The first
involved screening for G418 resistance, the second focused on selecting His+ clones
and the third identified His+ and G418 resistant clones.
Screening for G418 resistance
As described before, the pPic3.5K vector contains the bacterial kanamycinresistance gene that confers resistance to high levels of G418 to clones that contain
multiple copies of the vector (102). However, as was quickly discovered during the initial
attempts of growing the two strains, only X33 clones were able to survive on the YEPD
plus 0.25mg/mL G418 plates following electroporation. This indicated that X33 and
SMD1163 might differ in their sensitivity to the antibiotic. The literature supported this
finding and revealed that the protease-deficient strain, SMD1163, had a higher
sensitivity to G418 when compared to other strains like X33 or GS115 (116). It also
indicated that SMD1163 clones that contained just one gene copy were only able to
survive on plates supplemented with 0.025mg/mL G418 but clones with multi-copy
insertions were able to tolerate 0.05mg/mL or higher (116). Therefore for future
transformations we used 0.05mg/mL G418 as the initial cut-off for the SMD1163 clones
following electroporation.
While the issue between G418 and the SMD1163 clones was being resolved,
experiments with X33 clones began to move forward into the screening process. Largescale antibiotic-resistance screening of X33 clones was conducted by first filling a 96well plate with 100µL of sterile water per well.

Using sterilized toothpicks, single

colonies were then isolated and mixed with the water in a single well. Next, a multi57

channel pipette was used to dispense 5µL of the yeast/water mixture onto YEPD agar
plates that contained concentrations of G418 at 0.25, 0.75, 1.5 or 2.0mg/mL. The plates
were then placed in an incubator at 30°C and allowed to grow for 3-5 days. Out of the
almost four hundred X33 colonies screened, 9 were able to survive on the 2.0mg/ml
G418 plates (6 ZAAT and 3 MAAT, Figure 3.5). These colonies were then isolated and
grown in larger volumes for protein extraction (Section 3.5a).
Screening for His+ clones
As described previously, the SMD1163 lacks the HIS4 gene and consequently is
unable to grow on media that lacks histidine prior to transformation with an appropriate
vector. Therefore, the identification of His+ colonies is commonly one of the first steps in
the multi-copy selection process for his4 mutant strains, like SMD1163 (78). Following
electroporation, SMD1163 transformants were streaked directly onto plates that lacked
histidine [His (-) plates] and grown for 3-5 days. This resulted in only yeast cells that had
been correctly transformed with the pPic3.5K vector being able to survive.
Once the transformants were able to reach sufficient growth, 48 SMD1163
clones (24 per protein) were isolated and re-streaked onto new His (-) plates and grown
for an additional 3-5 days. This method, however, resulted in abundance of His+ clones.
While the SMD1163 strain is supposed to have a His! phenotype, there is a possibility
that some endogenous expression may still exist. Therefore 3-amino 1,2,4 triazole (3AT) was added to the second round of His (-) plates in an attempt to lower the amount
of His+ colonies present on the plates.
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A)

B)

Figure 3.5 Large-Scale Screening with G418. MAAT (A) and ZAAT (B) X33 clones grown on 0.25, 0.75, 1.5 and
2.0 mg/mL G418 (Left to Right respectively).
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This was done by spreading 0, 2, 3, 5, 10, 20 or 25mM 3-AT onto the YEPD agar
plates using glass beads, and allowing the plates to dry before streaking the colonies
onto them (8 colonies per plate). While there was some reduced growth on plates with
10mM, 20mM and 25mM 3-AT, the difference in growth was not significant. Therefore
this step was eliminated in future screenings. Overall, colonies that survived both
rounds of streaking on His (-) plates were considered His+ and were used either for
protein extraction (Section 3.5b) or for subsequent antibiotic testing.
Selecting for G418 resistant, His+ clones
SMD1163 transformants were also screened for multi-copy integrations by
selecting for His+, G418 resistant clones as described in the literature (78,81). This was
accomplished by first plating the transformants onto His(-) plates directly after
electroporation and allowing them to grow for 3-5 days. After the colonies displayed
sufficient growth, they were then isolated and mixed with 100µL of sterile water in a 96well plate. The yeast/water mixture was then spotted onto YEPD agar plates containing
G418 at 0.05, 0.10, 0.15 or 0.20mg/mL. The plates were then incubated at 30ºC for 3-5
days.
Using this method, approximately 400 His+ SMD1163 transformants were
isolated and screened for G418 resistance. Thirteen of these, 6 MAAT and 7 ZAAT,
were able to survive on plates containing 0.15mg/mL G418 and therefore were chosen
for protein extraction (Section 3.5).
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3.4 Protein Gel Electrophoresis and Western Blot Analysis
Following the identification of clones that contained multi-copy integrations of our
genes, the clones were then induced to promote protein expression. Our proteins of
interests were then extracted (Section 3.5) and purified (Section 3.6) through a series of
different methods and techniques. During this process, it was important to verify that our
protein was still present in the samples being tested. Therefore throughout these
experiments, a small portion of our samples were removed and analyzed by protein gel
electrophoresis and Western blot analysis. This section will discuss the methods used in
order to perform such analyses, the results of which are discussed in their appropriate
sections.

a) Protein Gel Electrophoresis
Electrophoresis, in general, is a common method of using an electric field to
separate macromolecules. In SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
specifically, a polyacrylamide gel is used as a support medium and sodium dodecyl
sulfate (SDS) is used to linearize the proteins by denaturing them. Protein separation by
SDS-PAGE can be used to estimate the relative molecular mass of proteins as well as
the relative abundance, distribution and purity of proteins within a sample (117). SDSPAGE experiments were conducted using NuPage® Novex ® 4-12% Bis-Tris Mini Gels
(Invitrogen) and performed under denaturing conditions (according to manufacture’s
instructions). Gels were then analyzed by 1) Coomassie stain 2) Silver stain and/or 3)
by Western blot analysis. Human !1-Antitrypsin (MP Biomedicals Inc.), which has a
molecular weight of 52kDa, was used as a positive control for these analyses.
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Coomassie Staining
Coomassie Brilliant Blue staining is a fast, inexpensive and fairly reliable
quantitative staining method that has a sensitivity of approximately 100ng (118).
Coomassie staining was conducted by covering the gel with the dye (50% methanol,
10% acetic acid, 1% Brillant Blue R-250) and microwaving the gel for 10 seconds. The
stain was then decanted and de-stain (50% methanol, 10% acetic acid) was added to
the gel and allowed to incubate on a rotating platform for 30 minutes. The de-stain was
then replaced with Mili-Q water and incubated on the rotating platform once more until
bands reached their desired clarity.
Silver Staining
Silver staining is another popular method of detecting proteins after protein gel
electrophoresis. Some advantages of silver staining include, but are not limited to,
sensitivity in the low nanogram range and compatibility with downstream processing
such as mass spectrometry analysis (118,119).
Silver staining was performed on a rotating platform using the SilverSNAP® Stain
Kit II (Pierce) according to the manufacture’s instructions. Briefly this involved washing
the gel for two 5 minute time periods in ultrapure water and then fixing the gel in a 30%
ethanol: 10% acetic acid solution for two 15 minutes incubations. The gel was then
washed twice in 10% ethanol for 5 minutes each, followed by two washings with
ultrapure water, once again, 5 minutes long each. A sensitizer working solution (50µL
sensitizer with 25mL water) was prepared and added to the gel for 1 minute. Following,
two 1 minute washes with ultrapure water, a stain working solution (0.5mL Enhancer
with 25mL Stain) was then added to the gel for 30 minutes. The gel was then washed
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twice with ultrapure water for 20 seconds and then developed with the developer
working solution (0.5mL Enhancer with 25mL Developer) until bands appeared. The
reaction was then stopped with 5% acetic acid for 10 minutes (120).

b) Western Blot Analysis
Western blotting, also known as immunoblotting, identifies target proteins among
a sample by exploiting antibody specificity to the target protein. Proteins are typically
separated first by electrophoresis and then transferred onto membranes (usually
Polyvinylidene fluoride [PVDF] or nitrocellulose). The membrane, referred to as a blot, is
then covered with a primary antibody specific for the target protein and then with a
secondary antibody (anti-immunoglobulin) that is labeled with enzymes, radioisoptoes
or other marker compounds used for detection (121).
Following separation by SDS-PAGE, proteins were transferred onto 0.45µm
nitrocellulose membranes (Invitrogen) as outlined in the NuPAGE® Technical Guide
(122). Proteins were transferred at 30V for 1 hour using 1X NuPAGE® Transfer Buffer
with 10% methanol in an XCell II™ Blot Module (Invitrogen). Once the proteins were
successfully transferred onto the nitrocellulose membrane, they were ready for Western
blot analysis, which was performed using the SNAP i.d. Protein Detection System by
Millipore.
The procedure was performed as indicated in manufacture’s manual (123) using
Tris-buffered Saline (TBS) with 0.1% Tween 20 as a wash buffer (TBS-T). Tween 20
was used in the wash buffer to help reduce solution surface tensions and to ensure
even antibody distribution during incubation (123). The blot blocking solution, which was
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added to help reduce non-specific antibody binding, consisted of either 1% Bovine
Serum Albumin (BSA) or 0.5% Casein dissolved in TBS-T. The primary antibody was a
mouse Monoclonal Anti-!1-Antitrypsin antibody (Abcam) at 1:4000 dilution and the
secondary antibody was a Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG
(H+L) antibody (Jackson ImmunoResearch) at 1:10000 dilution.

Detection of the

membrane was done using Santa Cruz Western blotting Luminol Reagent and exposing
the membrane to the reagent for 1 minute in a dark drawer. The membrane was then
exposed to autoradiography film and developed using Kodak supplies.

3.5 Extraction of MAAT and ZAAT proteins from P. pastoris strains
While the aforementioned issues regarding SMD1163’s sensitivity to G418 were
being resolved, it was decided that experiments with the X33 clones should continue in
order to help identify and optimize conditions prior to large-scale production. One such
condition was to determine the optimal time post-induction to harvest.

a) Optimizing Induction Time in X33 clones
According to Levina et al (100), the induction period should be between 17 and
72 hours. Given such a broad range of time, an experiment was conducted in order to
narrow down the optimal induction time needed for our proteins of interest.
This was accomplished by selecting 1 MAAT and 3 ZAAT clones identified by the
large-scale antibiotic resistance screening to inoculate 50mL of YEPD overnight at 30°C
shaking (225 rpm). The cells were then transferred to a 50mL conical centrifuge tube,
spun down at 4000xg for 5 minutes, washed with sterile water, and spun again at
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4000xg for 5 minutes.

Once pelleted, they were then re-suspended in 50mL of

Induction media (1% yeast extract, 2% peptone, 100mM potassium phosphate, pH 6.0,
1.34% Yeast Nitrogen Base with Ammonium Sulfate without Amino Acids, 4x10-5%
biotin and 0.5% methanol), poured into a 250mL flask and grown in a shaker (225rpm,
30°C) for a total of 96-hours.
After every 24-hours of growth, 10mL of culture was removed from the flask and
transferred to a 15mL conical centrifuge tube. Meanwhile, 5% methanol was added to
the remaining culture at 1/200 of its volume and then placed back into the shaker
(225rpm, 30°C). The 10mL that had been removed was pelleted at 4000xg for 5
minutes, washed with sterile water, and pelleted again at 4000xg for 5 minutes. The
pellet was then weighed and stored at -20°C until all samples were ready for lysis.
X33 yeast cells were lysed by mechanically breaking the cells directly into lithium
dodecyl sulfate (LDS) sample buffer. This allowed us to load the samples directly onto a
SDS-PAGE gel for analysis. Briefly, for every gram of wet cell paste, 1 gram of 0.5mm
glass beads, 1mL of NuPAGE® LDS Sample Buffer (Invitrogen), and 50µL of Protease
inhibitor Cocktail Set III, EDTA-Free (EMD4Biosciences) were added to the frozen cell
paste. DTT was added to the LDS buffer so that the final concentration of DTT was
100mM. The cells were then vortexed twice for 2.5 minutes each, and spun down in a
micro-centrifuge at max speed for 1 minute. The supernatant was then removed and
saved for further analysis via protein gel electrophoresis and Western blot analysis
(Section 3.4b). This allowed us to identify expression levels for each time point.
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An initial look at the MAAT samples displayed a faint band at ~55kDa for the 24hour induction time point but not for the other time points (Figure 3.6A). However when
these same samples were re-analyzed alongside those from the three ZAAT samples,
no expression was detected at all (Figure 3.6B). Given the band seen in the original
Western blot (Figure 3.6A, lane 3), it was decided at the time of the study that
harvesting should occur after a 24-hour post-induction time period.
Closer inspection of this Western blot later on, suggested that the band could be
the result of a spillover from the positive control since it is at the same exact molecular
weight. This would indicate that the monoclonal antibody used at this time was
ineffective at detecting our protein. One explanation could be that the antibody, which
was raised against Human AAT, might have not been able to detect our proteins, which
were synthesized in P. pastoris, due differences in glycosylation or protein production
within the organisms (discussed further in Section 3.5b).
Another explanation could be that perhaps our genes had not been properly
integrated into the P. pastoris genome. Although not performed at the time, this could
have been confirmed via PCR analysis as described in the Multi-copy Pichia Expression
Manual (110).
Lastly, the lack of detection could be the result of our proteins being degrading by
proteases present in the X33 strain. Therefore, in hopes of resolving some of the
inconsistency seen in the Western blots, focus was switched at this point from the X33
clones to the protease-deficient SMD1163 clones.
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Figure 3.6 Optimizing Induction Time in X33 clones. (A) An initial look at different
induction times for MAAT protein production indicated that cells should be harvested 24hours post induction. (B) However when samples where re-analyzed alongside ZAAT
samples, no expression was detected. This later gave rise to the possibility that the
band seen 24-hours post induction could have been a result of spillover from the
positive control, Human AAT. Nevertheless at the time of the study, it was decided that
harvesting would occur after a 24-hour post-induction time period. This was based on
the original interpretation of the Western blot seen in (A). A mouse monoclonal !1Antitrypsin antibody (1:4000 dilution) was used for the detection of AAT proteins.
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b) Identification of High-expression SMD1163 clones
Once we were finally able to perform in vivo screening for multiple insertions in
SMD1163, identified colonies were then isolated and analyzed in order to detect which
ones had the highest expression for our proteins of interest. This was performed by first
growing the clones in 10mL YEPD overnight in a test tube rotator at 30°C. The following
morning, the cells were spun down in a 15mL conical centrifuge tube at 4000xg for 5
minutes and then washed with 10mL of sterile water. The cells were then spun again at
4000xg for 5 minutes and re-suspended in 10mL of Induction media. Once more the
cells were placed in a test tube rotator and induced for 24-hours at 30°C. An incubation
of 24-hours was used based on our previous induction results with the X33 clones
(Figure 3.6A).
After the 24-hour induction period was over, the cells were centrifuged at 4000xg
for 5 minutes, and washed with sterile water. The water was then aspirated down to
1mL in which the cells were re-suspended. The mixture was transferred to a 2mL
microcentrifuge tube, placed in a microcentrifuge, and spun at max speed for 1 minute.
The supernatant was then removed and the pellet was weighed.
In order to determine which clone had the highest expression levels for MAAT or
ZAAT, the cells were lysed and then analyzed via protein gel electrophoresis and
Western blot analysis. Once more when we used a monoclonal antibody for our
Western blots, we observed no expression even after 5 minutes of exposure (Figure
3.7A).
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Figure 3.7 Identification of High-Expression SMD1163 Clones. (A) Once more
attempts at using a monoclonal antibody were made. However after a 5-minute
exposure, protein was still undetectable. (B) Samples were then diluted 1:10 and
analyzed via Siler staining. This revealed a ~50kDa band (blue arrow) in each of our
samples that was predicted to be our proteins of interests. (C) When the Western blot
was repeated, this time using a polyclonal antibody (30 second exposure time), a
~50kDa band (red arrow) was once again observed in each sample. This band was also
thought to represent our proteins of interest. Human AAT protein (MP Biomedicals, Inc)
served as a positive control for the described experiments.
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We next tried concentrating and diluting the samples in order to help increase the
resolution of our detection methods. However, when the samples were concentrated 5x
by a spin column with a 30kb molecular cut-off, there was still no detection by Western
blot and our Silver stain was inconclusive (not shown). On the other hand, when
samples were diluted 1:10, we were able to detect a band just slightly below our positive
control (around 50kDa) that was believed to be our proteins of interest (Figure 3.7B).
Samples were then sent off for mass spectrometry analysis in order to verify this, the
results of which indicated that the band present could be our AAT proteins but was not
100% conclusive.
Since the monoclonal antibody proved ineffective in detecting our proteins of
interest, we decided to switch to a rabbit polyclonal anti-human !1-Antitrypsin antibody
(Sigma) for the primary antibody and a Peroxidase-conjugated AffiniPure Goat AntiRabbit IgG (H+L) antibody (Jackson ImmunoResearch) as the secondary. Once the
antibody was switched to a polyclonal, we were finally able to see some expression on
our Western blots (~50kDa). However this also resulted in increased background noise
that could have been the result of non-specific binding (Figure 3.7C). Increasing the
TBS-T amount used during washings, as well as increasing its number of applications,
helped to resolve this issue. It wasn’t until we decided to change lysis methods that
were we finally able to determine which clones had the highest expression levels for our
proteins of interest.
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c) Optimizing Cell Lysis
Although our initial method of lysing the yeast cells directly into LDS buffer was
thought to be effective (Figure 3.7B), LDS is an anionic detergent and therefore might
interfere with our downstream ion exchange chromatography methods. Ultimately it was
only used for quick identification of clones that had the highest concentration of protein
expressed.
In hopes of finding a more chromatography-friendly lysis method, a chemical
method of lysis was introduced. This method involved adding Y-PER® Yeast Protein
Extraction Reagent from Thermo Scientific (2.5µL/mg wet cell paste), DTT (final
concentration 100mM), and Protease inhibitor Cocktail Set III, EDTA-Free (50µL/g wet
cell paste) to the frozen yeast cells. Next, the cell mixture was agitated at room
temperature for 20 minutes and transferred to a 2mL microcentrifuge tube. The tubes
were then placed into a microcentrifuge and spun at max speed for 10 minutes. The
supernatant was then removed and saved for further analysis (Figure 3.8).
In changing lysis methods it was important to verify that the chemical method
was as effective, if not more so, than the physical method. Therefore, a 10mL culture
was split into two 5mL aliquots; one that was lysed with LDS and the other was lysed
with Y-PER®. The results, as visualized by Western blot (Figure 3.8B) and Comassie
stain (Figure 3.8A), indicated that chemical lysis with Y-PER® was in fact a better lysis
method then the mechanical one. This can be seen in the fact that both detection
methods display bigger bands at ~50kDa for the Y-PER® samples when compared to
the LDS samples.
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Figure 3.8 Lysis Method Comparisons: (A) Coomassie stain gel and (B)Western blot indicating differences
between physical lysis with glass beads and LDS (LDS) and chemical lysis using Yeast Protein Extraction Reagent
(Y-PER®). Arrows indicate where AAT proteins were predicted to be located. Polyclonal anti-AAT antibody used in
1:3000 dilutions for Western blot. Human !1-Antitryspin served as a positive control for experiments.
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This is especially true for the Western blot which only showed expression in the
Y-PER® samples at ~50kDa but not in the LDS samples (Figure 3.8B). From these
results, we were also able to determine that MAAT-1 and ZAAT-2 had the highest
protein expression levels of the samples tested. Therefore these two colonies were restreaked onto YEPD + 0.05mg/mL plates and used for large-scale extraction methods.

d) Large-Scale Induction and Harvesting of SMD1163 clones
Once we were able to determine which clones had the highest expression levels
and our conditions were optimized on a small-scale, protein expression was produced
on a larger-scale (500-1000mL cultures). First, previously selected MAAT and ZAAT
SMD1163 colonies (Figure 3.8) were streaked onto YEPD agar plates with 50µg/mL
G418 to verify the viability of clones. Once this was accomplished, they were then
grown in 50mL YEPD in a shaker (225rpm) overnight at 30°C.

The next day, the

overnight culture was transferred to a baffled flask that contained 500-1000mL of YEPD
and placed in the shaker (225rpm) to once more grow overnight at 30°C.
The following day, the cultures were split up into 250mL centrifuge containers
and spun at 4000xg for 5 minutes. Cells were then washed with sterile water and
pelleted down again at 4000xg for 5 minutes. The pelleted cells were then resuspended in 250mL of Inducing media, transferred to a new sterile baffled flask, and
grown for 24-hours in a shaker (225rpm) at 30°C. Once 24-hours had elapsed, the cells
were split into 50mL aliquots and centrifuged at 4000xg for 5 minutes. They were then
washed with sterile water, spun again at 4000xg for 5 minutes with the resulting pellets
weighed and then stored at -20°C until needed for lysis.
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3.6 Protein Purification
After large-scale MAAT and ZAAT protein expression was completed, the target
proteins were then isolated and purified from the other proteins within the samples as
described in this section. In general, proteins can be purified through techniques that
separate them based on differences in specific properties such as charge, size,
hydrophobicity and ligand specificity (124). Typically protein purification is accomplished
through the combination of more than one of these techniques. For our experiments we
exploited differences in charge (ion exchange) and size (gel filtration) in order to purify
MAAT and ZAAT.

a) Anion Exchange Chromatography
Ion exchange chromatography (IEX) is a widespread protein purification
technique that is based on a reversible interaction between charged proteins and an
oppositely charged chromatography medium. There are two types of IEX: 1) cation
exchange, in which positively charged molecules are attracted to a negatively charged
solid support, and 2) anion exchange, where negatively charged molecules are
attracted to a positively charged solid support (125,126). Since the isoelectric point of
AAT varies from 4.9 to 5.1 (127), anion exchange was used to assist with purification of
the target proteins. Specifically Quaternary amine (Q)-Sepharose, a strong anion
exchange chromatography matrix, was used for this purification step.
Lab-Made Q-Sepharose Chromatography Columns
Before proceeding to an automated purification process of our proteins, a series
of purification experiments using lab-made columns were first performed to ensure that
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conditions were optimized. Buffers chosen for these experiments were based on a
protocol for plasma AAT purification (128). Approximately 5mL of Q-Sepharose Fast
Flow (GE Healthcare Life Sciences) was poured into a 10mL pipette, which had steel
wool previously packed into the tip, and allowed to settle. Next 5mL of wash buffer (WB,
2.5M NaCl, 0.1M Tris-HCl, pH 8.0, 5mM EDTA) was added to the column and allowed
to flowthrough, followed by 5mL of equilibrate buffer (EB, 0.1M Tris-HCl pH 8.0, 5mM
EDTA). Around 500µL of sample was then added to the column and flow through from
this point on was saved for further analysis.
The column was then washed twice with 5mL EB and then treated with a salt
gradient that would separate the target proteins from other proteins in the sample. This
salt gradient consisted of 0, 0.2, 0.4 and 1M NaCl dissolved in our EB. The addition of
the gradient to the column consisted of two 5mL washings for each salt concentration,
with the exception of 1M NaCl, which had four washings. The column was washed four
times with 1M NaCl to ensure that all protein had been removed from the column.
It was predicted that our proteins of interest would elute in the 0.4M NaCl range,
therefore the flowthrough for these washings were collected in 1mL aliquots while the
other concentrations were collected in 15mL conical centrifuge tubes. Samples of all
the collected flowthroughs were run on a SDS-PAGE gel and analyzed with Coomassie,
Silver staining and/or Western blotting, as previously described (Section 3.4), in order to
verify the presence of our protein.
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As shown in Figure 3.9A and C, our Q-Sepharose column was able to reduce the
number of proteins present in the sample (ZAAT unpurified versus Q1-4). Among the
bands indicted in this figure, the band at ~49kDa, in particular, was thought to be our
ZAAT protein. When a Western blot (Figure 3.9B) was done to confirm this however, the
band shifted down and was identified at ~40kDa. This could mean a number of different
things. The first, is that the sample had been stored at 4°C for about a week before the
Western blot analysis was performed. During this time the protein could have been
degraded, therefore resulting in the smaller band observed. Doing the Western blot
directly after purification and storing the samples with protease inhibitors are two things
that could have been implemented to prevent this from occurring.
Another possibility is that our polyclonal antibody was binding to Pichia pastorsis
proteins

instead

of

our

AAT

proteins.

In

fact,

a

quick

BLAST®

search

(http://blast.ncbi.nlm.nih.gov) revealed several P. pastoris proteins that were shown to
have sequence homology to our AAT proteins. Among these, two proteins were of
particular interest: Mu3-like subunit of the clathrin associated protein complex (AP-3)
and a hypothetical protein. The Mu3-like subunit was shown to be 52kDa (same as our
positive control) and had a max identity score of 34% (E value of 0.005). The
hypothetical protein had a molecular weight of 36.4kDa (similar to the band seen in
Figure 3.9B) and a max identity score of 25% (E value of 0.020). Given these
parameters, its is possible that our polyclonal antibody (epitope unknown) could be
identifying these proteins instead of our AAT proteins.
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Figure 3.9 Protein Purification Analysis and Verification. (A) Purification of ZAAT
using a lab-made Q-Sepharose chromatography column. Samples were visualized with
Silver stain, in which Q1-4 represents fractions collected at 0.4M NaCl from the
experiment. (B) Western blot and (C) Silver stain of another Q-Sepharose
chromatography expeirment (Q1-4, lab-made column) and a Gel Filtration
Chromatography (GFC 1-2) expeirment. Protein in Western blot detected by rabbit
polycolonal Human AAT antibody 1:2000 dilution. (D) ZAAT sample purified using a
HiTrap Q-FF column followed by Superdex 75 10/300 column and visualized by
Coomassie stain. Blue box depicts area in which proteins were predicted to be located.
Human AAT protein served as a positive control for the described experiments
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Figure 3.9 Continued.
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To verify this, we could have transferred our SDS-PAGE gels to a PVDF
membrane instead of a nitrocellulose one. One of the advantages of using a PVDF
membrane is that it can be directly used for N-terminal sequencing (129), which would
allow us to identify what exactly our Western blot was detecting. N-terminal sequencing
could have also been conducted using gel pieces containing the bands of interest that
had been extracted from a SDS-PAGE gel stained with Coomassie.
Automated Q-Sepharose Chromatography
Since our Silver stained gels led us to believe that we could elute our proteins of
interest with the lab-made column protocol, we decided to move on to a more
automated system that would eventually allow us to do large-scale purification. Samples
were loaded onto a BioLogic DuoFlow chromatography system (Bio-Rad) that was fitted
with a 1-mL HiTrap Q-FF column (GE Healthcare Life Sciences). The column was
equilibrated with 1mL of Buffer A (0.1M Tris-HCl pH 8.0, 5mM EDTA) at a flow rate of
1mL/min. Proteins were then eluted with a linear gradient of 0–40% Buffer B (Buffer A +
1 M NaCl) at a flow rate of 1mL/min and a total volume of 20mL. Next, 5mL of Buffer B
ran through the column at 1mL/min, followed by 10mL of Buffer A at 1mL/min.
Throughout the program fractions were monitored by a BioLogic QuadTec
UV/Vis detector (280nm wavelength) and then collected in 0.5mL aliquots. At the end of
the program, a report was generated (Figure 3.10A) that displayed the detector
readings, conductivity and the change in Buffer B percentage seen throughout. As
shown in Figure 3.10A, during one of our experiments a peak was detected in fractions
44-48 that had a max absorbance of 1.8 AU.
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Figure 3.10 BioLogic DuoFlow Run Reports. UV signal (Purple line), % Buffer B (blue
line) and conductivity (orange line) for samples run on BioLogic DuoFlow
chromatography system (Bio-Rad) that was fitted with (A) HiTrap Q-FF column or (B) a
Superdex 75 10/300 column (GE Health Life Sciences). Dotted lines in (B) represent
where fractions were collected for analysis.
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These fractions were then pooled together and analyzed by protein gel
electrophoresis. Run-off from the chromatography experiments were also saved and
analyzed.
Two runs were preformed using the HiTrap Q-FF column (Figure 3.9D). However
issues arose during the first run (Lane 4) that resulted in most of the protein being lost
to the run-off (Lane 6). We were able to resolve the problem during our second run
(Lane 5), which resulted in a greater amount of our protein being retained in the
fractions and not eluted in the run-off (Lane 7). For all four samples, the protein was
predicted to be located at the ~50kDa band.
Given these results, we concluded that we were able to isolate our target
proteins using the HiTrap Q-FF column. However, as also indicated by the amount of
bands present in Figure 3.9D, the protein was not very pure and would need follow-up
purification steps.

b) Size-Exclusion Chromatography
Size

exclusion

chromatography

(SEC),

also

known

as

gel

filtration

chromatography (GFC), separates proteins based solely on differences in their
molecular size. Separation is achieved due to the porous matrix packed in a
chromatographic column. Molecules applied to the column display different degrees of
access within the matrix based on their size. Smaller molecules can easily enter/exit the
pores freely, thereby prolonging their navigation through the matrix. Larger molecules,
on the other hand, are excluded from entering the pores and are instead swept through
the column by the aqueous buffer (mobile phase) that is ran though the column. This
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allows the proteins within a specific sample to elute in decreasing order of size, which
can be detected by an in-line UV monitor. Due to its low resolution though, SEC is
frequently used as a final polishing technique to remove any remaining contaminants
from the target protein (130).
SEC was performed using a BioLogic DuoFlow chromatography system fitted
with a Superdex 75 10/300 column (GE Health Life Sciences). This column has a
separation range for molecules between 3,000 and 70,000kDa and a bed dimension of
10 x 300mm (131). A program was initiated in which 500µL of the sample was injected
onto the column at a flow rate of 0.25mL/min. The mobile phase (Water/0.05% TFA) ran
through the column at a flow rate of 0.25mL/min for a total of 50mL. Once more
fractions were monitored by a BioLogic QuadTec UV/Vis detector (280nm wavelength)
and then collected in 0.25mL aliquots throughout the experiment.
At the end of the program, a report was generated (Figure 3.10B) that displayed
the detector readings, and conductivity seen throughout. As seen in Figure 3.10B, a
peak was detected in fractions 28-32 that had a max absorbance of 0.84 AU. These
fractions were then pooled together and analyzed by protein gel electrophoresis and
Western blotting (Figure 3.9B-D).
Surprisingly the SDS-Page gels displayed no protein bands for the SEC fractions
after treatment with either Coomassie or Silver stain. This was true regardless if the
sample had been previously purified with a lab-made Q Sepharose column (Figure
3.9C) or with the HiTrap Q-FF column (Figure 3.9D). Even after Western blot analysis,
we were still unable to detect protein following SEC (Figure 3.9B). This could be the
result of a number of different things. For example, the proteins may have degraded
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during the time they were purified until the time they were analyzed. This could be
especially true for the samples purified by a lab-made Q Sepharose column followed by
SEC (Figure 3.9B and C), in which almost a week went by between purification and
analysis. Although the samples were stored at 4°C during this time, the proteins may
have still degraded during this time as discussed previously. For the samples purified by
HiTrap Q-FF and SEC (Figure 3.9D) however, analysis was performed with 24-hours of
purification, therefore reducing the likelihood of protein degradation for these samples.
Another reason for this phenomenon could be as simple as not enough protein was
added to the Superdex column and therefore, upon fractionation, the protein became
too dilute. This dilution could reduce the protein concentration to levels that are not
detectable by our analysis methods. Determining the protein concentration by BCA or
Bradford Assay prior to SEC and before protein gel electrophoresis would help to
determine if this is indeed the case and if samples need to be concentrated or not.

3.7 Discussion
Upon the completion of the described procedures in this chapter, several
different factors regarding the production of M and ZAAT in P. pastoris were concluded.
For starters, according to Levina et al (100), the induction time for optimal expression is
between 17-72 hours. However in our hands, expression was only detectable after 24hours. While this was later brought into question, we were able to show that this
induction time, while maybe not optimal, was sufficient to express our proteins.
In addition, the vector used in the original paper (pHil-D2) only contained the
HIS4 marker and was not suitable for multi-copy integrations. Our vector (pPic3.5K), on
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the other hand, contained both the HIS4 marker and the bacterial KanR gene, the
combination of which drastically limited the amount of prospective clones by identifying
yeast colonies with multi-copy integrations.
Lastly, by comparing a physical method, similar to that seen in the original
paper, to a chemical method, such as Y-PER® , we were able to show that the chemical
method is actually a better form of lysis. These conditions helped to lay the foundation
for future experiments conducted in our laboratory.
Unfortunately the various analyses performed on the pooled fractions from both
the Q-Sepharose and SEC experiments proved to be inconclusive overall. After several
more attempts at the described procedure, it was determined that the current methods
were unable to produce the quantity and purity of protein needed for future experiments.
Therefore we decided to take a different approach, in which the cDNA was re-designed
to include a Histidine tag that could be exploited during the purification process and
hopefully improve our results (Chapter 4 and 5)
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CHAPTER 4:
USING SITE-DIRECTED MUTAGENESIS TO
CREATE TAGGED !1-ANTITRYPSIN PROTEINS

4.1 Introduction
Not that long ago if scientists wanted to study a specific mutation, they would
have to conduct phenotypic screenings after the isolated gene was treated with
mutagenic agents. The screenings were not only time-consuming but would often miss
lethal or non-phenotypically observable mutations. In addition, treatment with mutagenic
agents would commonly result in mutations being randomly distributed throughout the
gene, instead of specific locations. (132).
Today however, mutagenesis is typically achieved through either polymerasechain reaction (PCR) or non-PCR methods. In these methods, mutations are created
though codon changes at specified residues in order to produce amino acid
substitutions. This process is commonly referred to as Site-Directed Mutagenesis
(SDM) (132,133). Over the past three decades, several different SDM methods have
been proposed (133-141), some of which are now commercially available as SDM kits.
One of the most common methods of SDM is the QuikChange method, which
utilizes complementary primer pairs in a single PCR to rapidly introduce point mutations
into sequences of interest (141,142). After thermocycling, the product is then treated
with the restriction enzyme DpnI, which targets methylated and hemimethylated DNA.
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Since DNA isolated in almost all E. coli strains is dam methylated, DpnI only targets the
parental DNA, and leaves the newly synthesized DNA intact (136,142).
In this chapter, we will discuss attempts that were made to add a hexa histidinetag (6xHis-tag) to AAT cDNA through two different versions of the QuikChange method.
The first method is a two-step process in which the forward primer (binds to the
‘antisense’ strand to create a new ‘sense’ strand) and reverse primer (binds to the
‘sense’ strand to create a new ‘antisense’ strand) are placed into separate tubes for one
round of PCR and then combined for a second PCR (Figure 4.1). The second method
follows the traditional QuikChange approach where both primers are used in a single
PCR (Figure 4.2).

4.2 Plasmids and Primers
a) DNA Plasmids
Site-directed mutagenesis experiments were conducted using glycerol stocks of
DH5! cells that had been transformed with MAAT or ZAAT cDNA ligated into the
pPic3.5K vector (Section 3.2). To increase the amount of available cDNA, cells were
grown overnight in 100mL LB media and then isolated using the S.N.A.P. MidiPrep Kit.
The viability of the newly isolated cDNA was confirmed through restriction enzyme
digestion, prior to the SDM experiments. Digestion was performed for 1 hour at 37°C in
the presence of either BamH I by itself, EcoR I and BamH I together, or no restriction
enzyme.
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Figure 4.1. Flow chart of the Two-Step Site-Directed Mutagenesis Method. The
parental DNA is shown in gray and the two PCR synthesized strands are in blue and
purple. The letter X marks the position of the mutation
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Figure 4.2. Flow Chart of the Single-Step Site Directed Mutagenesis Method. The
parental DNA is shown in gray and the PCR synthesized strands in blue and purple.
The letter X marks the position of the mutation.

88

Once complete, a sample of the products was run on 1% agarose gel, which was
then stained with ethidium bromide and photographed under UV light (Figure 4.3). As
expected, the combined digestion of EcoR I and BamH I (lanes 4 and 7) resulted in two
distinct bands, one of which was the pPic3.5K (~9kb) and the other, AAT cDNA
(~1.2kb). On the other hand, when the cDNA was treated with BamH I alone (lanes 3
and 6), only one band was visible on the gel (~10kb), indicating that it had been properly
linearized. Lastly cDNA that not been treated with any restriction enzymes (lanes 2 and
5) displayed supercoiling and a thick band around 10.2kb. Overall, these results
indicated that the cDNA was still viable and could be used for our SDM experiments.

b) Primer Design
The QuikChange Primer Design website (www.agilent.com/genomics/qcpd) was
used to create complementary primers. These primers contained an 18bp segment that
would add a hexa histidine-tag (6xHis-tag) to the N-terminal of our previously
synthesized cDNA constructs (Section 3.2a). This website follows commonly employed
guidelines for double-primer PCR reactions, including: 1) primer sequences must be
complementary to each other, 2) mutation located in the middle of the primers 3) Primer
length should include 10-15 nucleotides (nt) on either side of mutation, 4) a GC content
of 40-70%, 5) sequence starts and ends with one or more G or C base, and 6) the
melting temperature (Tm) should be !78ºC (141,142). Primers (Table 4.1) were ordered
from Sigma and used without further purification.
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Figure 4.3. Restriction Enzyme Digest of MAAT and ZAAT with BamH I and EcoR I
to confirm DNA viability. As expected, uncut MAAT and ZAAT (lanes 2 and 5)
resulted in DNA supercoiling whereas a double digest with BamH I and EcoR I (lanes 4
and 7), caused the AAT sequence to be isolated from the pPic3.5K vector (1.2kb and
9kb respectively). HyperLadder I (Bioline) was used as the molecular weight marker in
all gels.
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HisAAT-F

Primer Name

CTCCTTGGGGGTCTTCATGATGATGATGATGATGCATGGTGGATCCCTTC

GAAGGGATCCACCATGCATCATCATCATCATCATGAAGACCCCCAAGGAG

Primer Sequence 5' to 3'

Table 4.1 Forward (-F) and Reverse (-R) Primer Sequences for the insertion of an 18nt segment
coding for a 6XHis tag. Insertion is indicated in red.

HisAAT-R

PfuUltra® HF DNA polymerase

QuiKSolution reagent

10X PfuUltra® reaction buffer

25mM dNTP mix

Reverse primer

Forward primer

Template plasmid DNA

50µL

2.5 U

3 µL

5 µL

1µL

-

40pmol

~50ng

Reaction 1

50µL

2.5 U

3 µL

5 µL

1µL

40pmol

-

~50ng

Reaction 2

50µL

2.5 U

3 µL

5 µL

1µL

8.4pmol

8.4pmol

~50ng

Reaction A

Table 4.2. PCR Reaction Components and Concentrations. Reaction 1 and 2 are for the Two-Step Site
Directed Mutagenesis method and Reaction A is for the Single-Step Site-directed Mutagenesis method,

Final Volume
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The QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies),
which contains the PfuUltra® High-Fidelity DNA Polymerase, was used to carry out all
SDM experiments. The kit also contains a pWhitescript 4.5-kb plasmid that served as a
control for our experiments.

4.3 Two-Step Site-Directed Mutagenesis
The protocol used for the two-step site-directed mutagenesis (2SDM)
experiments was based on a procedure from the Soderling lab (Duke University, (143))
that combined elements from the “QuikChange II XL” manual (142) with those from an
article published by Wang and Malcolm in 1999 (136). The method starts with the
simultaneous PCR of two separate reactions, each one containing separate primers.
The products of these parallel reactions are then combined into a single tube and PCR
is performed once more (see Table 4.2 for reaction components and concentrations).

a) PCR Conditions
PCR tubes containing the reaction mixes were placed into the thermocylcer, and
after an initial denaturation step at 95ºC for 1 minute, PCR was conducted for 10 cycles.
Each PCR cycle consisted of denaturation at 95ºC for 1 minute, primer annealing at
55ºC for 90 seconds and DNA synthesis at 68ºC for 10 minutes (one minute per kb of
plasmid length). Afterwards, 25µL from each reaction was then mixed together into a
fresh 0.2mL PCR tube, along with 0.75µL of fresh PfuUltra® High-Fidelity DNA
Polymerase.

92

The tube, now containing both forward and reverse primers, was then placed
back into the thermocycler and another round of PCR began. After an initial
denaturation step that was carried out at 95ºC for 1 minute, PCR was conducted for 18
cycles with denaturation at 95ºC for 1 minute, primer annealing at 55ºC for 90 seconds
and DNA synthesis at 68ºC for 10 minutes (one minute per kb of plasmid length). The
reaction was then held at 4ºC until it ready for removal.

b) Amplification Analysis
After the PCR tube was removed from the thermocycler, 1µL of DpnI (200U/µL)
was added and the tube was incubated at 37ºC for at least 1 hour. This allowed the
DpnI endonuclease to digest the methylated parental plasmid strands, leaving only the
newly synthesized strands behind. After DpnI digestion was completed, amplification
was confirmed by running a sample of the products on a 1% agarose gel, which was
then stained with ethidium bromide and photographed under UV light (Figure 4.4).
Upon the successful implementation of the 2SDM experiment and DpnI
digestion, we would expect to see a single band around 10.2kb on the agarose gel.
However, as seen in Figure 4.4A, amplification of either MAAT or ZAAT cDNA was
undetectable by agarose gel electrophoresis during the first few attempts at 2SDM. On
the other hand, we were able to observe a band at approximately 5kb for our control,
indicating that our experimental set-up was successful. Therefore the problem was
thought to lie either with the cDNA or the primers used for our samples.
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A)

B)

C)

Figure 4.4 Results from Two-Step Site-Directed Mutagenesis. A) Original attempt at 2SDM with wrong primer
concentrations. B) Second attempt at 2SDM with corrected primer concentration. C) Further analysis of 2SDM results that
included looking at Reaction 1 (forward) and 2 (reverse) alone and digesting the combined reaction with Bam H1 and
EcoR I instead of DpnI. HyperLadder I was used as the molecular weight marker in all gels.
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A closer look at the primers revealed that there had been a miscalculation during
the initial resuspension of the reverse primer that caused the primer concentration to be
almost half of what was originally expected. This revelation provided a possible
explanation for the lack of amplification observed, and once remedied, 2SDM was
attempted again. However, even with the corrected primer concentrations, amplification
of our samples was still not detected (Figure 4.4B).
In an attempt to rule out DpnI digestion as a cause for this phenomenon,
agarose gel electrophoresis was used to compare the DpnI digested products with
those digested by BamH I and EcoR I as well as Reaction 1 and 2 undigested. If
successful, we predicted that digestion of the 2SDM products with both BamH I and
EcoR I would result in two bands: one at ~9kb and the other at ~1.2kb. Once more we
anticipated that DpnI would produce a single band at ~10.2kb and undigested samples
would display supercoiling. Unfortunately there was no DNA detected in any of the
samples analyzed aside from our control (Figure 4.4C).
Lastly, the integrity of the DNA was once more verified by restriction enzyme
digestion with BamH I and EcoR I, which result in the successful separation of the AAT
cDNA from the pPic3.5K vector (not shown). Since it seemed that after several attempts
the 2SDM method was still unable to provide any detectable amplification of our
samples, we transitioned to the traditional single-step site directed mutagenesis method
next.
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4.4 Single-Step Site Directed Mutagenesis
Unlike the 2SDM method, the single-step site directed mutagenesis (1SDM)
method consists of only one PCR reaction that contains both the forward and reverse
primers in the same tube. 1SDM experiments were conducted by following the
procedure outlined in the QuikChange II XL Site Directed Mutagenesis Kit manual
(142). A list of the different reaction components and concentrations used are recorded
in Table 4.2. After an initial denaturation step at 95ºC for 1 minute, PCR was conducted
for 18 cycles with denaturation at 95ºC for 50 seconds, primer annealing at 60ºC for 50
seconds and DNA synthesis at 68ºC for 10 minutes (one minute per kb of plasmid
length). The primers were further allowed to extend at 68ºC for 7 minutes and then held
at 4ºC till the reaction was ready for removal.
Once the tube was removed from the thermocycler, 1µL of DpnI was added to
the reaction and DpnI digestion was carried out at 37ºC for at least 1 hour. This was
then confirmed by agarose gel electrophoresis, as described before. Again,
amplification of our samples was not detectable by agarose gel electrophoresis (Figure
4.5A). This proved true even if the PCR product was analyzed prior to digestion (Lanes
2 and 4). In fact, our results mirrored those seen when no DNA was added to our
control reactions (Figure 4.5A, Lane 7). Thinking that something may be wrong with our
cDNA, we decided to once more validate its integrity through restriction enzyme
digestion using EcoR I and BamH I. As expected, this produced two bands on the
agarose gel—the first at ~9.0kb (pPic3.5K) and the second at ~1.2kb (isolated AAT)—
indicting that our cDNA was still intact and could be isolated from the pPic3.5K vector as
before (Figure 4.5B).
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A)

B)

Figure 4.5 Results from Single-Step Site-Directed Mutagenesis. A) Attempt at
employing the 1SDM method. Products were either digested with DpnI or ran on the gel
without any type of digestion. The control reaction was also performed with and without
the provided cDNA. B) Confirmation that our cDNA was still valid and could be digested
by BamH I and EcoR I. HyperLadder I was used as a molecular weight marker for both
gels.
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4.5 Discussion
Overall, our attempts at site-directed mutagenesis were unsuccessful, possibly
for a multitude of different reasons. A common issue with using complementary primers,
such as those needed for SDM, is the formation of “primer-dimers” occurring within the
reaction. These primer-dimers can result from partial annealing of a primer with a
second primer in the reaction and can drastically reduce the amount of transformants
produced (141). Such a phenomenon could possibly explain why the SDM experiments
in this chapter did not perform as well as had been expected. The presence of primerdimers would also explain the band at ~100kb seen in our agarose gels (Figure 4.4 and
4.5A). One way that we could reduce the formation of primer-dimers is to increase the
annealing temperature closer to the melting temperature of our primers. To find the
optimal temperature for annealing we could perform a round of touchdown-PCR (a
method that gradually decreases the annealing temperature over the course of
successive cycles) as described in the literature (144-146).
Another explanation could be that since our primers consisted of 50nt, a
relatively long length for a primer, some secondary structure formation could have
occurred, which would prohibit it from binding to the cDNA (142). However several
studies have been published (136,141,147,148) in which complementary primers that
are the same size or longer than ours have been successful in SDM experiments. In
order to help resolve this issue, we could once more alter the PCR conditions for the
SDM experiments. This could involve optimizing the annealing temperature as
described previously or increasing the denaturation temperature to 98°C. Another option
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would be to linearize our cDNA prior to PCR, since linear DNA is able to denature more
efficiently than supercoiled DNA (149).
Lastly, a mistake during the ordering and synthesis of the primers could account
for the lack of amplification seen in our experiments. Closer inspection of our primers
revealed that this might have indeed been the case. The sequence that was generated,
and thereby used in our experiments, contained an extra guanine (G) in both the
forward and reverse primers (Table 4.3) that shifted the whole sequence and disrupted
the primer-template duplex (Table 4.4 compared to Table 4.5). Such a disruption would
promote primer-dimer formations (100% complementary) while simultaneously reducing
primer-template annealing (increased multiple mismatches). If these experiments were
to be conducted again, new primers should be ordered and tested prior to the
implementation of the other methods described in this section.
Despite several attempts at implementing the 2SDM and the 1SDM methods,
ultimately we were unsuccessful at amplifying our target DNA so that it contained the
18nt insertion. Therefore it was decided that the cDNA should be redesigned and
reordered so that it contained a 6xHis-tag on the N-terminal of our proteins. The
methods and results of which are discussed in the next chapter (Chapter 5).
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Primer Sequence 5' to 3'
CGAAGGGATCCACCATGCATCATCATCATCATCATGAAGACCCCCAAGGAG
CTCCTTGGGGGTCTTCATGATGATGATGATGATGCATGGTGGATCCCTTCG

Table 4.3. Corrected Design for Forward (-F) and Reverse (-R) Primers for the insertion of an 18nt
segment coding for a 6XHis tag. Letters in blue indicted missing residues, orange indicates added
residues and insertion is indicated in red.
Primer Name
HisAAT-F
HisAAT-R

Primer-Template Duplex

Table 4.4 Primer-Template Duplex for Corrected Primers
Primer Name
HisAAT-F

HisAAT-R

5'-cgaaggatccaccatgcatcatcatcatcatcatgaagacccccaaggag-3'
||||||||||||||||
||||||||||||||||
taagcttcctaggtggtac------------------cttctgggggttcctctac
attcgaaggatccaccatg------------------gaagacccccaaggagatg
||||||||||||||||
||||||||||||||||
3'-gcttcctaggtggtacgtagtagtagtagtagtacttctgggggttcctc-5'

Primer-Template Duplex
5'- gaagggatccaccatgcatcatcatcatcatcatgaagacccccaaggag-3'

Table 4.5. Primer-Template Duplex for Ordered Primers
Primer Name
HisAAT-F

HisAAT-R

|||||
||||||||||||||||
taagcttcctaggtggtac------------------cttctgggggttcctctac
attcgaaggatccaccatg------------------gaagacccccaaggagatg
|||||||||||||||
||||||||||||
3'- cttcctaggtggtacgtagtagtagtagtagtacttctggggggttcctc-5'
100

CHAPTER 5:
EXPRESSION AND PURIFICATION OF TAGGED
!1-ANTITRYPSIN PROTEINS

5.1 Introduction
Protein affinity tags are highly popular tools for the purification of recombinant
proteins. One reason for this is that they can provide a hundred- or even thousand-fold
purification increase when compared to untagged purifications techniques. In addition,
the use of affinity tags allows a generalized protocol to be implemented to purify a
diversity of proteins, thereby saving both time and money (150).
Over the past 20 years, several different types of affinity tags have become
commercially available, with the most common being the polyhistidine affinity tag. This
tag typically consists of six consecutive histidine residues (hexa-histidine) but can range
in length from two to ten histidine residues (150,151).

While polyhistidine fusion

proteins are conventionally purified using immobilized Ni2+, other metals such as Ca2+,
Co2+, Cu2+, Zn2+, or Fe3+ can also be used (151,152). This purification process can
result in fairly pure protein (>80%) after only one chromatographic step (151).
Initial endeavors at producing untagged, properly folded and active !1-Antitrypsin
(AAT) recombinant protein were ultimately unable to produce the desired protein
concentrations (Chapter 3). Therefore to increase selectivity and ease of purification, it
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was decided that a hexa-histidine tag (6xHis-tag) should be added to the N-terminal of
the proteins.
However, as discussed in Chapter 4, several complications arose during
preliminary attempts at adding this tag to wild-type (M) and mutant (Z) AAT cDNA.
Therefore, new cDNA constructs containing the 6xHis-tag were synthesized for both
MAAT and ZAAT. This chapter will discuss the manipulation of these constructs into the
Pichia pastoris vector, pPic3.5K, as well as the expression, and purification of MAAT
and ZAAT protein from P. pastoris.

5.2 DNA Manipulation
Prior to expression in P. pastoris, cDNA constructs for both the wild-type and
mutant forms of AAT were once more synthesized and then subcloned into the pPic3.5k
vector using the gram-negative bacterium, Escherichia coli. The techniques performed
for this process are described below and are similar to those discussed in Section 3.2.

a) Tagged AAT DNA Constructs:
The new MAAT and ZAAT cDNA constructs (Table 5.1), ordered from Blue
Heron Biotech, were again flanked by BamH I and EcoR I restriction sites to assist with
subcloning as previously described (Section 3.2a). The Kozak sequence was also
added to ensure proper translation in Pichia pastoris and cytosolic protein production
was assured though the removal of the signal peptide sequence. Unlike the previously
synthesized cDNA, the new constructs also included a 6xHis-tag and a tobacco etch
virus (TEV) cleavage site at the N-terminus of the cDNA.
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Table 5.1. Protein Sequences for Hexa-Histidine Tagged MAAT and ZAAT Proteins. Sequences are based on cDNA
generated from Blue Heron Biotech. Restriction enzyme sites are depicted in blue, Kozak sequence for pPic3.5K in green,
6xHis-tag in orange, TEV cleavage site in purple and Z mutation (E342K) shown in red. Both proteins are predicted to
have a molecular weight of approximately 47kDa and an isolectric point of 5.56 (www.expasy.org).

MAAT

GSTMHHHHHHENLYFQGMEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFS
PVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVD
KFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEV
KDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDII
TKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTE
AAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK-EF

Protein Sequences

ZAAT

GSTMHHHHHHENLYFQGMEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFS
PVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVD
KFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEV
KDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDII
TKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDKKGTE
AAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK-EF
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To limit any effects that the 6xHis-tag might have had on the already fragile
ZAAT structure, a TEV cleavage site was added to the sequence. This site (ENLYFQG)
is recognized by a TEV protease that binds and cleaves the cDNA at a specific location
(between Q and G), thereby removing the 6xHis-tag as well as anything upstream of it
(153). Constructs were first synthesized into the Blue Heron pUCminusMCS vector
(Figure 3.1) and then subcloned into the pPic3.5K (Figure 3.2) prior to P. pastoris
expression.

b) Subcloning of AAT cDNA
Subcloning of MAAT and ZAAT cDNA into the pPic3.5K vector was once more
performed though a series of steps that included plasmid amplification and isolation,
restriction enzyme digestion, and DNA ligation. As described before (Section 3.2b),
plasmid amplification was conducted through the transformation of Max Efficiency®
DH5!™ Competent Cells with MAAT and ZAAT cDNA. The amplified AAT DNA was
then isolated and cleaned using the S.N.A.P. Midiprep kit, followed by digestion with
EcoR I and BamH I restriction enzymes. The restriction enzymes excised MAAT and
ZAAT cDNA from its original vector, and the resulting fragment was separated via
agarose gel electrophoresis. This can be seen in Figure 5.1A and B where plasmids
treated with both EcoR I and Bam H I resulted in two bands, one for the pUCminusMCS
vector (~3kb) and the other the AAT DNA fragment (~1.2kb). DNA that was treated with
only BamH I was linearized and resulted in a single band at ~4.2kb whereas undigested
DNA underwent supercoiling. The DNA fragment was then purified from the gel using
the S.N.A.P. Gel Purification kit as per manufacture’s instructions.
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A)

B)

C)

Figure 5.1. Manipulations of Tagged !1-Antitrypsin DNA in E. coli. Restriction
enzyme digestion of MAAT (A) and ZAAT (B) with EcoR I and BamH I prior to ligation
into pPic3.5K. (C) Following ligation, DNA was linearized with Sal I and Sac I restriction
enzymes. Gels were made in 1% agarose, stained with ethidium bromide and
photographed under UV light. Hyperladder I was used for all DNA gels.
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After the DNA fragments were isolated from the agarose gel, they were then
ligated into the pPic3.5K vector, as described previously (Section 3.2b). The plasmids
were then linearized overnight with either Sac I or Sal I so that the genes can be
inserted either at the AOX1 locus (Sac I) or the His4 locus (Sal I) within the P. pastoris
genome.

Following

linearization,

the

DNA

was

separated

via

agraose

gel

electrophoresis in which linearized DNA (either by BamH I, Sac I, or Sal I) produced a
single band at ~10.2kb. Undigested and double digested (BamH I and EcoR I) were
also analyzed as controls (Figure 5.1C). DNA clean-up was once more performed using
the Wizard® SV Gel and PCR Clean-Up System, as per the manufacture’s instructions.

5.3 P. pastoris Expression, Induction and Harvesting
The expression, induction and harvesting of MAAT and ZAAT protein from P.
pastoris was performed similar to what was described in Sections 3.4 and 3.5. To
summarize, SMD1163 cells were first made competent by following the protocol
outlined by Wu and Letchworth (111) and then electroporated with linearized MAAT or
ZAAT DNA using a MicroPulser Electroporator. Cells were thought to be osmotically
sensitive during and following electroporation (103), therefore before plating, cells are
incubated in Sorbitol for one hour at 30ºC, followed by an additional hour in a 1:1 mix of
Sorbitol and YEPD (Yeast extract, Peptone, and Dextrose). The transformed cells were
next spread onto YEPD agar plates with 0.05mg/mL G418 and placed into an incubator
at 30ºC for 3-5 days.
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a) Screening for multi-copy inserted clones
The pPic3.5K contains the bacterial kanamycin (KanR) gene that confers
resistance to G418 in Pichia pastoris. This resistance is dose dependent in that the
more copies of the gene that integrated into the genome, the higher the resistance that
is conferred upon the cells (78,102). Therefore, hyper-resistance to G418 was utilized to
screen for colonies carrying multiple copies of the KanR gene and thereby multiple
copies of the AAT genes. This was performed as previously described (Section 3.3b), in
which single SMD1163 colonies were mixed with 100µL of sterile water in a 96-well
plate and then spotted onto YEPD agar plates containing G418 at either 0.05, 0.10,
0.15 or 0.20mg/mL. The plates were then incubated at 30ºC for 3-5 days. Out of the
almost 200 colonies screened, only 10 (4 MAAT and 6 ZAAT) were able to survive on
the YEPD agar plates that contained higher amounts of G418. These 10 colonies were
isolated and then induced in 10mL of Induction media for 24-hours (based on our
previous findings from Section 3.5a). After the 24-hour induction time period, the cells
were then pelleted down and stored at -20°C until ready for lysis.
Protein expression levels of each colony were analyzed via Coomassie stain
and/or Western blot after lysis was completed (Section 3.5c). As seen in Figure 5.2A,
our Western blot analysis was able to detect protein bands just below 50kDa for each
sample. This weight is close to our predicted molecular weight of ~47kDa and is
comparable to what was observed by Levina et al (~45kDa). Of the samples tested,
MAAT-4 and ZAAT-6 indicated the highest protein expression levels. Therefore they
were re-streaked onto YEPD + 0.05mg/mL G418 plates and used in our extraction
methods.
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A)

B)

Figure 5.2. Expression, Induction and Harvesting of AAT protein from P. pastoris as analyzed by Western blot. (A)
Identification of high expression MAAT and ZAAT clones lysed with Y-PER®. As a result of this analysis, clones MAAT-4
and ZAAT-6 were selected for large-scale expression. (B) Verification of Induction Time for ZAAT-6 protein expression.
Cell lysates were prepared using YeastBuster™. Based on this blot, a 48-hour induction time was selected for optimal
expression. A polyclonal AAT antibody was used for both Western blots. Human AAT served as a positive control.
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b) Verifying length of Induction Time
Previously it was shown that an induction time of 24-hours was needed for
optimal expression of MAAT and ZAAT. However this was based on a Western blot that
used mouse monoclonal anti-!1-Antitrypsin antibody as the primary antibody (Figure
3.6A). As discussed in Section 3.5b, this antibody ended up not being able to identify
our protein of interests. Therefore the induction time needed to be verified using the
rabbit polyclonal anti-!1-Antitrypsin antibody.
This was performed as previously described (Section 3.5a), in which highexpression MAAT and ZAAT clones (Figure 5.2A) were first grown overnight (225rpm,
30°C) in 50mL of YEPD and then washed with sterile water. The cells were then
resuspended in 50mL of induction media and grown in a shaker (225rpm, 30°C) for a
total of 96-hours. After every 24-hours, 10mL of culture was removed, washed with
sterile water, and then weighed. Cell pellets were stored at -20°C until all samples were
ready for lysis.
The remaining culture received 5% methanol at 1/200 of its volume. This not only
helped to replenish the carbon source but also promote expression of our genes though
the AOX1 promoter. Once all the time points were collected, they were lysed and
analyzed using Coomassie staining and/or Western blot analysis.
Our previous results indicated that 24-hours was the induction time needed for
optimal expression. However, as seen in Figure 5.2B Lane 2, an induction time of 48hours showed the most expression (band once more at ~49kDa). This was shown to be
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true for both ZAAT and MAAT.

Therefore the induction time for P. pastoris was

changed to 48-hours for all future experiments.

c) Preparing Cell Lysates
As described in Section 3.5c, we were able to show that in our hands, the
chemical method of cell lysis was more efficient than the mechanical method. In those
experiments the Y-PER® reagent was used and seemed to be compatible with the
downstream chromatography experiments at the time. However when samples that
been extracted using Y-PER® were applied to Ni-NTA columns (Section 5.4a) it was
quickly observed that this particular reagent was not compatible with these columns.
Upon the addition of the samples, a discoloration of the resin would occur (would
turn brown in color) that would result in most of the protein being eluted directly into the
wash (Figure5.3, ~50kDa bands). This discoloration is known to be a sign of Nickel ions
being removed or reduced within the resin usually due to reducing agents (i.e. DTT)
present in the buffers (154).
Therefore an alternative lysis method was quickly sought out. YeastBuster™
Protein Extraction Reagent (Novagen®), another commercially available lysis reagent,
was soon selected based on its known compatibility with the Ni-NTA columns and easy
to use protocol (154,155).
Briefly, frozen cell pellets were resuspended in room temperature YeastBuster™
(5mL/g wet cell paste), 100X tris(hydroxypropyl)phosphine solution (THP, 50µL/g wet
cell paste) and Protease Inhibitor Cocktail Set III, EDTA-Free (50µL/g wet cell paste).
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$"#

Figure 5.3: Y-PER® Lysed Samples after IMAC Purification. Samples were lysed
with the Y-PER® reagent and then purified using Imobilized-metal Affinty
Chromatography. The lysis reagent was shown to be incomatible with our columns
which resulted in most of the protein being eluted during the washing steps. This was
verified by Western blot with an (A) anti-6xHis antibody (1:1000 dilution, Abcam) and a
(B) polyclonal AAT antibody (1:2000 dilution, Sigma). Arrows indicate where our
proteins were predicated to be located.
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The cell suspension was then incubated for 20 minutes at room temperature on either a
shaking platform or rotating mixer at a slow setting.

Cell debris was removed by

centrifugation at 4000xg for 30 minutes at 4°C and the resulting supernatant was
transferred to a fresh tube (156). Samples extracted using YeastBuster™ were shown
to be comparable to those using Y-PER® (Figure 5.2A versus B).
While we chose to stick to a chemical form of lysis, there are several other
alternatives that we could have pursued. The first, and perhaps simplest, would be to
lyse the yeast cells with Y-PER® but without the presence of the reducing agent, DTT.
While this method was attempted, the results were inconclusive and therefore should be
reverified. Another alternative would be to perform a buffer exchange in which the YPER® would be replaced with the binding buffer used in the affinity chromatography
experiments (Section 5.4).
Lastly, new Ni-NTA columns that are known to be compatible with Y-PER®, such
as those provided in the Y-PER® 6xHis Fusion Protein Purification Kit (Pierce), could
have been ordered and used for purification. At the time of this study however, it was
decided that we should maintain our current columns and instead alter the reagent used
for lysis as described above.

d) Large-scale Induction and Harvesting
After the above changes in our methodology were established, MAAT and ZAAT
colonies were expressed and extracted from large cultures of 500-1000mL YEPD. This
was performed as previously described (Section 3.5d), in which a two-day overnight
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culture was produced first. A starter culture of 50mL YEPD was grown overnight and
then used to inoculate a second culture in 500-1000mL of YEPD.
Once the final overnight culture was prepared, the cells were washed with sterile
water, resupended in Induction media, and induced in a shaker (225rpm, 30°C) for 48hours. After the first 24-hours, the culture was removed from the shaker so that 5%
methanol could be added to it at 1/200 of its volume. The culture was then returned to
the shaker for an additional 24-hours of induction. Once the cells had been induced for
a total of 48-hours, they were removed from the shaker, washed with sterile and then
stored at -20°C until ready for lysis with the YeastBuster™ reagent.

5.4 Protein Purification
Following protein extraction using YeastBuster™, samples were then purified
through a combination of Immobilized-Metal Affinity Chromatography and Anion
Exchange Chromatography. The techniques implemented during these purification
processes will be explained in this section.

a) Immobilized-Metal Affinity Chromatography
As discussed in the introduction of this chapter (Section 5.1), polyhistidine fusion
proteins are readily purified using immobilized metals, a technique called ImmobilizedMetal Affinity Chromatography (IMAC). This technique exploits the affinity that occurs in
an aqueous solution between certain transition metal ions, like Ni2+, and specific amino
acids residues, such as histidine (152). Compared to other affinity chromatography
techniques, IMAC is not highly specific. Nevertheless, it is often the method of choice
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when a combination of high protein purity and quick purification are needed. In general,
IMAC has several benefits to its use, including ligand stability, mild elution conditions,
high protein loading, and low cost (157).
For our experiments the agarose-based IMAC resin Nickel-Nitriloacetic acid (NiNTA) was used to bind and elute the His-tagged MAAT and ZAAT proteins from two
different types of columns. The first type was a His-Bind® Column (Novagen®) that
was pre-packaged with 1.25mL bed volume of Ni2+-charged His-Bind Resin.

The

second type involved 1.25mL of Ni-NTA His-Bind Resin (Novagen®) being added to a
5mL pipette that had steel wool previously packed into the tip. The protocol for both of
these columns followed the procedure outlined in the His-Bind Kit Manual (155).
First, 20mL of 1x Binding Buffer (H-BB, 50mM NaH2PO4, pH 8.0; 300mM NaCl;
10mM imidazole), 10mL of 1x Wash Buffer (H-WB, 50mM NaH2PO4, pH 8.0; 300mM
NaCl; 20mM imidazole) and 5mL of 1x Elute Buffer (H-EB, 50mM NaH2PO4, pH 8.0;
300mM NaCl; 250mM imidazole) were prepared per column. Next the columns were
equilibrated with 10mL of H-BB, making sure to allow the entire buffer volume to flow
through the column. Once all the H-BB had flowed through the column, the sample was
loaded onto the column (up to 10mg of target protein) with the flow through collected
from that point forward.
The column was then washed with 10mL of H-BB followed by 10mL of H-WB.
AAT protein was then eluted from the column with 5mL of H-EB and captured in 1mL
fractions. The fractions and washes that were collected throughout were then ran on a
SDS-PAGE gel and analyzed by Coomassie staining and/or Western blot to verify the
presence of protein (methods described in Section 3.4).
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Initially our protein detection via Coomassie staining was very faint (Figure 5.4A)
but it was soon revealed that one of the reasons for this was that we were
underwhelming the column and therefore very little protein would be eluted. An example
of this is seen in Figure 5.4A fraction B, which resulted in a faint band being identified at
~50kDa (predicted size of our proteins of interest).
Once we figured this out and started to increase our sample load, we were able
to better detect our protein on the SDS-PAGE gels. However as seen in Figure 5.4B,
when the sample amount was increased, we also increased the amount of
contaminants present (bands at ~38kDa). Therefore additional purification steps were
necessary.

b) Anion Exchange Chromatography
Previously when we performed anion exchange chromatography using QSepharose (Section 3.6a) we used buffers similar to those involved in purification of
AAT from blood plasma (128). However upon closer inspection, and several
unsuccessful attempts at purifying tagged protein using this protocol, it was decided that
the buffers should be switched to closely mimic those described by Levina et al
(100,158). Therefore, purification of tagged MAAT and ZAAT using Q-Sepharose
chromatography was conducted as follows. First 1.25mL of Q-Sepharose Fast Flow was
added to a 5mL pipette that had steel wool previously packed into the tip. Next, 1mL of
wash buffer (Q-WB, 50mM Tris-HCL, pH8.0 and 300mM NaCl) was allowed to run
through the column followed by two 1mL applications of the equilibrate buffer (Q-EB,
50mM Tri-HCL, pH 8.0, and 75mM NaCl).
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A)

B)

Figure 5.4 IMAC Purification of ZAAT sample. (A) During initial attempts at IMAC purification, small amounts of sample
were applied to the column and were therefore underwhelming it. This prevented us from being able to detect our protein
very clearly by Coomassie staining. (B) However once we increased the sample amount, we were able to better detect the
protein bands. Unfortunately this also increased the amount of contaminants detected as well (bands ~38kDa). Blue box
indicates with protein of interest was predicted to be located.
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Once the column was equilibrated, the sample (diluted 1:3 with Q-EB) was added
to the column and the flow through was collected from that point forward. The column
was then washed twice with 1mL Q-EB and then treated with a salt gradient of 75, 100,
125, 150 and 175mM NaCl dissolved in the Q-EB. The gradient was added in two 1mL
applications for each NaCl concentration, followed by four 1mL applications of the QWB.
Fractions and washes collected throughout the chromatography experiment were
separated via SDS-PAGE, analyzed by Coomassie staining (Figure 5.5A) and then
confirmed by Western blotting (Figure 5.5B). Although both the Coomassie stained gel
and the Western blot showed bands at ~50kDa (Lanes 2-4 and 6), the positive control
(human AAT) in the same gels was calculated to be ~75kDa (Figure 5.5A, Lane 10),
well above the predicted mass (52kDa).
Fearing that that something could have occurred during electrophoresis that
would result in the weight discrepancy, the samples were run again on a new SDSPAGE gel. However the same phenomenon occurred in the new gels as well. This could
mean that there was something wrong with our positive control (such as aggregation)
and/or there was an issue with the molecular weight ladder used.
Using new human AAT as our positive control or changing the molecular weight
ladder used in our SDS-PAGE set-up could help to rule out these two possibilities. More
than likely the proteins at this molecular weight (~50kDa) are Pichia pastoris that similar
sequence to our AAT proteins and are therefore recognized by our polyclonal antibody
as discussed previously in Section 3.6b.
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A)

B)

Figure 5.5 Anion Exchange Purification. (A) Coomassie staining and (B) Western blot analysis of samples collected
after IMAC and Q-Sepharose chromatography. Letters A-E represent fractions collected during IMAC whereas #mM NaCl
indicates Q-Sepharose samples. Blue arrows indicate area where protein is predicted to be located and red arrows
reference contaminants.
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It should be noted that additional bands (~70kDa) were also observed by
Coomassie staining (Figure 5.5A) for our IMAC combined fractions (Lane 2) and our
300mM NaCl elution (Lane 9). Since these bands are closer in molecular weight to our
positive control, it is likely that this band is our protein of interest. However since our salt
gradient jumped from 175mM NaCl to 300mM NaCl, it is unclear at what concentration
the protein was actually eluted from. In addition the presence of several bands in our
300mM NaCl elutions (Figure 3.5B, Lanes 7 and 8) could indicate that we have purified
aggregated and monomeric AAT protein together at this concentration. This theory is
supported by Levina et al, in which their study eluted aggregated protein from 270290mM NaCl (100). Therefore the experiment would need to be repeated in order to
fully cover the missing range and pinpoint the necessary elution concentration.

5.5 Discussion
To summarize the procedures outlined in this chapter, cDNA for both MAAT and
ZAAT were re-synthesized to include a 6xHis-tag and TEV cleavage site on the Nterminus. Like the previous constructs, the new cDNA also contained several factors
needed throughout the expression and purification processes (Section 5.2a). The cDNA
was then subcloned into the pPic3.5K vector (Section 5.2b) and transformed into the
SMD1163 strain of P. pastoris through electroporation. Following electroporation, cells
with multiple copy integration events were selected based on their resistance to the
antibiotic, G418. SMD1163 clones that expressed the highest expression levels were
then induced for 48-hours followed by protein extraction using YeastBuster™ (Section
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5.3).

Finally, MAAT and ZAAT proteins were purified by Immobilized-Metal Affinity

Chromatography followed by Anion Exchange Chromatography (Section 5.4).
While it is plausible that we were successful at purifying MAAT and ZAAT
protein, there are still several conditions that are needed to optimized/ altered before
confirming the presence of our protein. The first would be to increase the amount of
yeast cells grown prior to lysis. With the methods discussed in this thesis, we were only
obtaining 20-30g of cells per liter, which is a low cell density for Pichia pastoris.
Fermentation, which can increase cell densities in P. pastoris to as high as 130g/L
(69,70), could be implemented In order to address the issue. By increasing the cell
density we would, in theory, also raise the amount of protein produced, thereby helping
to enhance our overall yield.
Another thing that could potentially help to boost our overall protein yield would
be to increase the amount of Induction media used so that it is equal to the volume of
the overnight cultures. Currently the induction media used is only 250mL, which is 2550% of the overnight culture volume. Therefore increasing the induction media volume
would help to ensure that all the yeast cells are induced equally.
Various aspects of the IMAC purification process would also need to be
optimized, the first of which would be to alter the buffer compositions. The buffers used
for IMAC purification were from the Ni-NTA buffer kit (Novagen®) and differed from
those used by Levina et al. In comparison, our wash buffer contained less NaCl
(300mM vs. 500mM) and slightly less imidazole (20mM vs. 25mM) then was reported in
the paper. In addition their elution buffer contained twice the amount of imidazole
(250mM vs. 500mM) and half the amount of NaCl (300mM vs.150mM). Since NaCl is
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used to prevent ionic interactions and imidazole is used to bind to Ni-NTA and compete
with histidine residues in the 6xHis-tag (154), the differences in the buffers could
account for some of the obstacles observed during IMAC purification. This would be
especially true for the elution buffer in which our conditions might have been to mild for
proper elution due the lower imidazole concentration. Such conditions could result in our
His-tagged protein to remain bound to the column and therefore reduce the amount
seen in our fractions.
Conversely an alternative explanation as to why we observed small amounts of
protein being eluted from our Ni-NTA columns is that our 6xHis-tag was hidden, either
fully or partially, within the protein. This would explain why we were able to still detect
our proteins of interests (~50kb) in the washes even after changing the lysis method
(Figure 5.4). To verify that our protein is indeed binding to the column, we could first run
the sample through the column as illustrated in Section 5.4a and then cleave the 6xHistag using a TEV protease. As previously described, the protease would remove the tag
and leave behind a single amino acid residue, causing our proteins to be eluted into the
wash during a second application of IMAC. This process would also help to remove
contaminants eluted with our protein during the first application. If this proves
unsuccessful, the proteins could alternatively be purified under denaturing conditions or
the 6xHis-tag could be moved to the C-terminal of the proteins (154).
Lastly, our anion exchange chromatography methods would need to be
optimized before we could be confident of protein purification. As discussed in Section
5.4b, it appears as if our protein was eluted at 300mM NaCl, but only after jumping from
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175mM NaCl buffer. Therefore, it would be necessary to attempt the described
experiments again but making sure to account for missing range of NaCl concentration.
It should be noted however, that even if the proteins elute somewhere between
175-300mM NaCl, it would still be outside of the range described by Levina et al.
According to their publication, monomeric AAT was eluted between 100-150mM NaCl,
cleaved protein was eluted at 150mM (ZAAT) or 190mM (MAAT) and polymers were
eluted at 270-290mM NaCl (100).
One explanation for why our proteins seem to be eluting at higher salt
concentrations than what has been reported could simply be that we are not adding
adequate amount of buffers though the column. Currently we were only applying two
bed volumes of buffer to the column at each salt concentration. Increasing this to at
least 5 bed volumes would be to ensure proper elution of proteins at each concentration
(124). Another reason could be because the samples are transferred directly from a
phosphate-based buffer during IMAC purification to a Tris-based buffer in Q-sepharose
chromatography. A consistent buffer base (either all phosphate-based or all Tris-based)
for our buffers or a buffer exchange between the chromatography steps could help
eliminate this issue.
Once all of these conditions have been optimized/altered, then we will be able to
confirm if the process we have outlined in this thesis would be successful at producing
and purifying active, and monomeric MAAT and ZAAT proteins.
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CHAPTER 6:
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Conclusions
Ever since the connection between Alpha1-Antritrypsin Deficiency and !1Antritrypsin (AAT) polymerization was established, there has existed a high demand for
recombinant AAT protein. This is especially true for the Z variant of AAT, which is very
prone to polymerization and thereby difficult to produce recombinantly. Over the years
several systems have been implemented to produce wild-type MAAT protein but it was
not until 2009 that recombinant ZAAT protein was successfully produced. The goal of
this thesis was to expand upon this original study in order to produce both untagged and
tagged versions of recombinant ZAAT protein using the methylotrophic yeast, Pichia
pastoris.
The expression and purification of untagged recombinant MAAT and ZAAT
protein was attempted first (Chapter 3). While the techniques used throughout this
process ended up being insufficient at producing protein at the quantity or purity
needed, they did lay the foundation for protein purification procedures implemented
throughout this thesis. These methods included in vivo screening of multiple gene
inserts, cell lysate preparation as well as induction and harvesting techniques.
Following the unsuccessful attempts at untagged protein purification, focus
shifted to the production of His-tagged recombinant ZAAT and MAAT protein. Initially
the addition of the 6xHis-tag was attempted via Site Directed Mutagenesis (Chapter 4).
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However, after a series of complications and the usage of two SDM methods, it was
decided that cDNA for MAAT and ZAAT would be resynthesized to include a 6xHis-tag.
Using these new constructs, the SMD1163 strain of P. pastoris was transformed by
electroporation and selected for multiple-copy insertions based on resistance to the
antibiotic, G418. Protein expression was induced for 48-hours prior to harvesting with a
chemical reagent. Our proteins were then purified though a combination of affinity
chromatography and anion exchange chromatography methods (Chapter 5).
Nonetheless several complications arose throughout this process, particularly
during the purification steps. These issues thereby prevent us from being able to state
with confidence that we obtained purified AAT protein. Some methods that can be
implemented to overcome these obstacles have been described throughout this thesis
and will also be reviewed in the next section. Overall, the techniques used and
suggested throughout this thesis provide a foundation for future endeavors of AAT
expression and purification from Pichia pastoris.

6.2 Future Directions
While we have made progress towards expressing and purifying AAT proteins
from Pichia pastoris, there are several areas within our methodology that would benefit
from optimization or modification. Such changes would us to determine if our techniques
are actually successful or not. For example, switching the yeast cells to a fermentor
instead of growing in a beveled flask in a shaker would increase the amount of cells
available and therefore amplify the amount of protein that can be purified. In addition,
increasing the amount of Induction media used may also help to enhance protein yields.
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As stated before, many of our obstacles occurred during the purification process.
Some things that could be attempted to overcome concerns occurring during affinity
chromatography include altering the buffers to more closely mimic those used by Levina
et al, purifying under denaturing conditions, and moving the 6xHis-tag to the C-terminus.
Another option would be to run the samples through the affinity chromatography column
twice. Prior to the second round however, samples would be cleaved with TEV protease
in order to remove the 6xHis-tag, thereby causing the protein of interest to elute into the
wash and separating it from any contaminants.
As for complications that arose during anion-exchange chromatography, altering
the salt gradient concentrations so that they fully cover the 75-300mM NaCl range
and/or increasing the buffer bed volume applied to the column might help to address
these obstacles. Lastly changing the buffers used throughout the purification process so
that they are all either phosphate-based or Tris-based may help to elevate some of the
problems encountered in this thesis.
Once purification of heterologous MAAT and ZAAT protein from P. pastoris is
shown to be successful, the structural, inhibitory, and polymerization characteristics of
the proteins will need to be verified. These characterizations will help to determine if the
proteins produced display the same attributes seen in AAT protein purified from Human
patient plasma.
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